

# **Hepatic transcriptome analysis of inter-family variability in flesh n-3 long-chain polyunsaturated fatty acid content in Atlantic salmon**

**Sofia Morais<sup>1</sup>§, John B Taggart<sup>1</sup>, Derrick R Guy<sup>2</sup>, J Gordon Bell<sup>1</sup>, Douglas R Tocher<sup>1</sup>**

<sup>1</sup>Institute of Aquaculture, University of Stirling, Stirling FK9 4LA, Scotland, UK

<sup>2</sup>Landcatch Natural Selection Ltd, Cooperage Way, Alloa, FK10 3LP, Scotland, UK

§Corresponding author

Email addresses:

SM: [sofia.morais@stir.ac.uk](mailto:sofia.morais@stir.ac.uk)

JBT: [j.b.taggart@stir.ac.uk](mailto:j.b.taggart@stir.ac.uk)

DRG: [derrick.guy@hendrix-genetics.com](mailto:derrick.guy@hendrix-genetics.com)

JGB: [g.j.bell@stir.ac.uk](mailto:g.j.bell@stir.ac.uk)

DRT: [d.r.tocher@stir.ac.uk](mailto:d.r.tocher@stir.ac.uk)

## **Abstract**

**Background:** Genetic selection of Atlantic salmon families better adapted to alternative feed formulations containing high levels of vegetable ingredients has been suggested to ensure sustainable growth of aquaculture. The present study aimed to identify molecular pathways that could underlie phenotypic differences in flesh n-3 long-chain polyunsaturated fatty acid (LC-PUFA) levels when fish are fed vegetable oil diets. Liver transcriptome was analyzed and compared in four families presenting higher or lower n-3 LC-PUFA contents at two contrasting flesh total lipid levels.

**Results:** The main effect of n-3 LC-PUFA contents was in the expression of immune response genes (38% of all significantly affected genes), broadly implicated in the modulation of inflammatory processes and innate immune response. Although genetic evaluations of traits used in the breeding program revealed that the chosen families were not balanced for viral disease resistance, this did not fully explain the preponderance of immune response genes in the transcriptomic analysis. Employing stringent statistical analysis no lipid metabolism genes were detected as being significantly altered in liver when comparing families with high and low n-3 LC-PUFA flesh contents. However, relaxing the statistical analysis enabled identification of potentially relevant effects, further studied by RT-qPCR, in cholesterol biosynthesis, lipoprotein metabolism and lipid transport, as well as eicosanoid metabolism particularly affecting the lipoxygenase pathway. Total lipid level in flesh also showed an important effect on immune response and 8% of significantly affected genes related to lipid metabolism, including a fatty acyl elongase (*elovl2*), an acyl carrier protein and stearoyl-CoA desaturase.

**Conclusions:** Inter-family differences in n-3 LC-PUFA content could not be related to effects on lipid metabolism, including transcriptional modulation of the LC-PUFA biosynthesis pathway. An association was found between flesh adiposity and n-3 LC-PUFA in regulation

of cholesterol biosynthesis, which was most likely explained by variation in tissue n-3 LC-PUFA levels regulating transcription of cholesterol metabolism genes through *srebp2*. A preponderance of immune response genes significantly affected by n-3 LC-PUFA contents could be potentially associated with disease resistance, possibly involving anti-inflammatory actions of tissue n-3 LC-PUFA through eicosanoid metabolism. This association may have been fortuitous, but it is important to clarify if this trait is included in future salmon breeding programmes.

## **Background**

Aquaculture is the fastest growing animal production activity worldwide, supplying an increasing proportion of fish for human consumption, estimated at around 50% of total supply in 2008 [1]. However, the growth of marine aquaculture is threatened by its excessive reliance on fishmeal (FM) and fish oil (FO) from wild stocks for the production of fish feeds, which is also an ecologically unsound practice. Almost 89% of the total global production of FO is currently used by aquaculture [2] and the future of this activity strongly depends on the reduction of dependency on FM and FO and its replacement with alternative ingredients, such as vegetable oils (VO) and plant meals, while maintaining fish welfare and health benefits for the human consumer. Fish are highly nutritious components of the human diet and the main source of essential n-3 long-chain polyunsaturated fatty acids (LC-PUFA). The beneficial effects of fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are numerous and important, including protection against a range of cardiovascular and inflammatory diseases, as well as neurological disorders [3]. Atlantic salmon (*Salmo salar*) can grow well on diets where FO has been completely replaced by VO but this results in lower levels of n-3 LC-PUFA in their flesh, compromising their nutritional value and health-promoting effects to the human consumer [4].

The use of selective breeding programs to enhance traits of commercial importance is becoming increasingly common in aquaculture [5]. It has been suggested that combining genetic selection for fish that are more efficient in retaining and/or biosynthesising n-3 LC-PUFA with changes in commercial diet formulations (i.e., higher levels of inclusion of VO) might be a viable strategy to meet growing worldwide demands for aquaculture products, without loss of nutritional value. Previous studies have shown wide individual variability in the capacity of Atlantic salmon to retain or synthesize n-3 LC-PUFA when fed VO diets [6]. Following this, Leaver et al. [7] demonstrated that deposition and/or retention in flesh of dietary n-3 LC-PUFA, EPA and DHA, is a highly heritable trait ( $h^2=0.77$ ) in salmon. These results have prompted further interest in large-scale in-depth studies exploring genotype  $\times$  nutrient interactions in salmon, analysing whether the genetic background of the fish could affect the physiological response to complete dietary replacement of FO by VO [8,9]. In the present study we investigated this further by analyzing the transcriptome from liver, the primary site of synthesis and export of lipids to extra-hepatic tissues including flesh, from four Atlantic salmon families phenotyped for different levels of flesh n-3 LC-PUFA content in response to a VO diet. The objective was to identify gene pathways and molecular mechanisms that might underlie differences in flesh n-3 LC-PUFA contents when salmon families were fed the same low LC-PUFA diet. Furthermore, because n-3 LC-PUFA level is a component of, and associated with total lipid content in a tissue, a factorial design was chosen in which families containing higher and lower proportions of flesh n-3 LC-PUFA were compared at similar flesh total lipid contents.

## **Results**

### **Family lipid contrasts**

Lipid analysis of fifty Atlantic salmon families showed flesh lipid levels ranging from 2.3 to 5.7% of wet weight, with relative and absolute n-3 LC-PUFA contents varying from 71 to

136 ( $\mu\text{g}/\text{mg}$  lipid) and 314 to 554 ( $\text{mg}/100\text{g}$  flesh), respectively. As expected, high correlations between lipid level and n-3 LC-PUFA content were observed ( $r = -0.65$  or  $0.70$  for relative and absolute contents, respectively), indicating that only families with near identical lipid levels should be compared to avoid confounding effects associated with the lipid level factor (additional file 1). Using these results, four families were identified; two with high (H) levels of lipid ( $5 \text{ g}/100\text{g}$  flesh), and two with low (L) levels of lipid ( $3.5 \text{ g}/100\text{g}$  flesh) and, within each level of total lipid, the two families had significantly contrasting relative n-3 LC-PUFA contents (similarly termed H and L). Therefore, the four families constituted a  $2 \times 2$  factorial design, labelling each family by the total lipid/n-3 LC-PUFA contrasts as LL, LH, HL and HH, respectively (Table 1), which allowed comparisons of n-3 LC-PUFA contents at a constant lipid level and, similarly, comparisons of total lipid at constant n-3 LC-PUFA levels.

### **Microarray analysis**

A two-way ANOVA analysis employing the Benjamini-Hochberg multiple testing correction (at a significance level of 0.05 and fold change cut-off of 1.2) was performed to assess significant effects of the factors 'n-3 LC-PUFA' and 'total lipid', which returned lists with 43, 109 and 66 entities for each factor and their interaction, respectively. These significant lists were then analyzed in detail and genes were categorized according to their biological function, in some cases inferred from mammalian homolog genes (Tables 2 and 3). Because the focus of this work was to identify genes that are specifically affected by the trait n-3 LC-PUFA content without the interference of total lipid level, the interaction between the two factors is not presented. Distribution of genes by categories of biological function (excluding 12-18% non-annotated probes, those representing the same gene or with a miscellaneous function) revealed that there was a preponderance of immune response genes significantly affected by both factors: 38% by 'n-3 LC-PUFA' and 29% by 'total lipid'. Gene Ontology

(GO) enrichment analysis, which enables the identification of GO terms significantly enriched in the input entity list when compared to the whole array dataset, revealed that this is a true over-representation in the list of genes significantly affected by the 'total lipid' factor (Additional file 2). In contrast, genes involved in the broad category of metabolism only corresponded to 21% of genes significantly affected by n-3 LC-PUFA content and 30% by the 'total lipid' factor. Surprisingly, no lipid metabolism genes were significantly altered in liver when comparing families with higher and lower contents of n-3 LC-PUFA in their flesh, while about 8% were significantly affected by flesh lipid level. Within these, noteworthy was the down-regulation of fatty acyl elongase (*elovl2*) and of acyl carrier protein transcripts in salmon having a higher lipid level in their flesh, independent of LC-PUFA content. On the other hand, stearyl-CoA desaturase was significantly up-regulated in fish with higher lipid levels in their flesh. The interaction between both factors is not presented but it did not substantially affect lipid metabolism genes. Finally, and in general, genes involved in regulation of transcription and signalling were also prevalent, 17% in response to 'n-3 LC-PUFA' and 12-13% to 'total lipid'.

Therefore, the results did not identify lipid metabolism pathways that might underlie differences in flesh n-3 LC-PUFA composition between families. However, previous studies demonstrated that hepatic metabolism genes typically show only low fold changes, even when comparing highly contrasting nutritional compositions (e.g., inclusion of 100% FO *versus* 100% VO in diets [8,9]), compared to immune response genes that tend to be regulated with higher magnitudes of change [10]. Hence, nutritional data such as the present data have been analysed previously without multiple testing correction and this was found to result in relevant biological interpretations, when validated by reverse transcription real time quantitative PCR (RT-qPCR) [9, 11]. For this reason, we examined the significant effects of 'n-3 LC-PUFA' without the correction, and from within the list containing 1951 features

(significance level, 0.05; fold change cut-off, 1.2), we identified and categorized all 48 lipid metabolism transcripts present (Table 4). An effect on cholesterol metabolism was apparent for the factor 'n-3 LC-PUFA', with several genes of the biosynthesis pathway and its regulation being down-regulated in fish with a high n-3 LC-PUFA phenotype. In addition, glycerophospholipid synthesis, lipid hydrolysis and eicosanoid synthesis and metabolism were also affected, while other genes were associated with lipid and fatty acid transport, fatty acid synthesis and regulation of lipid metabolism.

### **Validation of results by RT-qPCR**

To validate the microarray analysis results, expression of selected genes was quantified by RT-qPCR. These genes were chosen from lipid metabolism pathways that were more highly affected by the factor 'n-3 LC-PUFA', and also included immune response genes, which was the category most highly affected by both 'n-3 LC-PUFA' and 'total lipid' factors. In addition, the expression of two fatty acyl desaturases (*Δ5fad* and *Δ6fad*) and one elongase (*elovl2*), which are typically responsive to dietary levels of n-3 LC-PUFA were also determined. The LC-PUFA biosynthesis pathway was not identified by the microarray analysis as being differentially expressed in families with different n-3 LC-PUFA flesh contents but, given the potential importance of this pathway in determining n-3 PUFA phenotypes, we specifically aimed to verify this result. The RT-qPCR results confirmed that genes involved in LC-PUFA biosynthesis were not differentially expressed in families with higher and lower levels of n-3 LC-PUFA (Table 5). Furthermore, the RT-qPCR results confirmed significant down-regulation of genes involved in hepatic cholesterol biosynthesis, such as isopentenyl-diphosphate isomerase (*ipi*), 7-dehydrocholesterol reductase (*7dchr*) and sterol regulatory element-binding protein 2 (*srebp2*) in families containing higher levels of n-3 LC-PUFA in their flesh although this was only observed when this phenotype was also associated with low lipid level, except for *7dchr*, which was significantly down-regulated irrespective of lipid

level. With regards to lipoprotein metabolism (lipid transport) genes, general trends such as the magnitude and direction of change were broadly similar between the microarray and the RT-qPCR analysis for the high versus low n-3 LC-PUFA comparison at low lipid contents, although RT-qPCR results were not significant. In the case of high lipid contents, the match between microarray and RT-qPCR data was less consistent, except for lipoprotein lipase (*lpl*), which was similarly up-regulated albeit non-significantly. Up-regulation of the glycerophospholipid biosynthesis pathway in fish with higher n-3 LC-PUFA contents was also indicated when associated with high lipid levels, significant for monoacylglycerol O-acyltransferase 1 (*mgat*). With regards to the eicosanoid biosynthesis pathway, the microarray results could only be confirmed for arachidonic 5-lipoxygenase (*alox5*). Validation of lipid metabolism genes affected by the 'total lipid' factor (Table 6) confirmed the lower expression of *elovl2* in salmon presenting higher lipid levels in their flesh, independent of LC-PUFA content. Finally, good agreement was found between the microarray and RT-qPCR results for immune response genes in response to both 'n-3 LC-PUFA' (Table 5) and 'total lipid' (Table 6) factors.

### **Genetic evaluations**

Subsequent to the dietary trial and microarray analyses, genetic evaluations (estimated breeding values, EBVs) became available for a range of traits upon which the families are under active selection in the breeding program. Given the unexpectedly high preponderance of immune response genes identified by transcriptomic analysis, we investigated associations with traits that could potentially explain the gene expression data. In this respect, one of the most relevant traits was 'survival to infectious pancreatic necrosis (IPN) virus', known to be almost entirely controlled by a major QTL [12]. Genetic evaluations included data collected from a freshwater experimental IPN challenge on full-sibs from the same families as the trial fish. Examining the families, selected on their lipid phenotypes, used for transcriptomic

analysis it was seen that family HH, containing both high total lipid and high n-3 LC-PUFA flesh contents, also showed a high EBV for survival to IPN (selection differential on a standardized normal distribution = 1.86 standard deviations), contrasting with -0.83 (LL) - 0.99 (LH) and -1.28 (HL) for the other families, that could introduce a potential for bias in interpretation of the transcriptomic responses. However, no such imbalance was present in the lower lipid grouping, comparing families LL and LH (additional file 3).

## **Discussion**

The present study which ascertained lipid profiles of 50 Atlantic salmon families confirmed previous results showing important inter-family variation in the ability to retain n-3 LC-PUFA in the flesh when fish are fed diets with low levels of these fatty acids [7].

Furthermore, even though a high correlation was found between flesh lipid levels and n-3 LC-PUFA contents, families with the same total lipid level varied significantly in n-3 LC-PUFA contents. In the present study we did not examine whether these differences have a genetic basis, as this was established previously [7], but instead aimed to identify molecular pathways whose transcriptional regulation might underlie the phenotypic differences, independent of lipid content.

### **LC-PUFA biosynthesis**

Differences in flesh n-3 LC-PUFA content in individuals fed the same diet is likely to arise from either selective incorporation and retention of fatty acids supplied by the diet or from biosynthesis from precursors in tissues such as the liver. In the present study we performed a transcriptomic study to identify molecular mechanisms potentially underlying flesh n-3 LC-PUFA phenotypes. Expression of candidate genes of the LC-PUFA biosynthesis pathway were also quantified as there was good evidence that these genes are transcriptionally regulated and that mRNA levels correlate with enzymatic activity of this pathway [13,14], and so this appeared a likely mechanism that required specific investigation. Flesh was the

target tissue for analysis of the n-3 LC-PUFA retention trait because salmon accumulate lipid reserves in muscle and this is the main product for human consumption, and so its composition will affect the health-promoting properties of salmon. However, hepatic tissue was analyzed for effects on gene expression since the production of both LC-PUFA and the lipoproteins that transport them to the tissues takes place mainly in the liver [15].

The transcriptomic analysis revealed few effects of the n-3 LC-PUFA factor on metabolism in general and, in particular, a lack of effect on lipid metabolism genes, when the statistical analysis employed multiple testing correction. However, this correction is typically not used when examining effects of diet and genetic background on metabolic genes, which tend to show subtle, but physiologically relevant, changes (9,11,16). Without multiple testing correction we were able to identify pathways of lipid metabolism that might be altered in response to this factor, although a clear mechanism for the observed inter-family differences in n-3 LC-PUFA content was not identified. Potential effects on lipid transport and lipoprotein metabolism were indicated by the presence of two apolipoprotein A4 transcripts (*apoa4a* and *b*), a low density lipoprotein (LDL) receptor-related protein (*lrp1*) and a lipoprotein lipase (*lpl*) transcript in the microarray analysis, albeit these were not validated by RT-qPCR. In contrast, the RT-qPCR results clearly confirmed that the flesh n-3 LC-PUFA phenotype cannot be explained by transcriptional modulation of genes of LC-PUFA biosynthesis and so other mechanisms must be in operation. One hypothesis might be that phenotypic differences between families originates from the presence of different alleles of fatty acyl desaturases and/or elongases encoding proteins with altered biological activity or specificity, as described for the nematode *Caenorhabditis elegans* [17].

### **Effects of n-3 LC-PUFA flesh contents on hepatic cholesterol biosynthesis**

Within the lipid metabolism genes that were differentially expressed in the liver between fish showing higher or lower n-3 LC-PUFA contents in flesh, the category of cholesterol

biosynthesis and its regulation was the most apparent, based on the number of probes for interrelated genes present in this list, all with coordinated regulation indicating reduced cholesterol biosynthesis in salmon having higher flesh n-3 LC-PUFA. In addition, and inferred by the magnitude of change (i.e., fold-changes), effects were more pronounced in fish containing lower flesh lipid levels. These results were confirmed by quantifying the expression of three enzymes catalyzing steps in cholesterol biosynthesis (*mev*, *ipi* and *7dchr*) as well as *srebp2*, a transcription factor that regulates cholesterol synthesis [18]. Furthermore, the RT-qPCR analysis indicated that this regulation was only associated with lower flesh lipid levels given that in the high lipid group only *7dchr* was down-regulated. Therefore, this experiment confirmed previous studies suggesting an association between flesh adiposity and n-3 LC-PUFA in the regulation of cholesterol biosynthesis in Atlantic salmon families, with lean fish showing a higher responsiveness to n-3 LC-PUFA [8]. However, an important novel outcome of the present study was the demonstration that the previous results were not solely a consequence of a higher dietary intake of cholesterol supplied by a FO diet in contrast to a VO diet [11] but also resulted from higher incorporation and increased tissue levels of n-3 LC-PUFA. The likely explanation for these results is the role of n-3 LC-PUFA as regulators of gene transcription, including some implicated in cholesterol biosynthesis, mediated by *srebp2* [18-20]. Nonetheless, the mechanism for why this response was only observed when associated with low flesh lipid levels requires clarification. Recent studies showed that lean humans are also more responsive, in terms of plasma lipid and lipoprotein composition, to cholesterol-reducing diets containing lower levels of saturated fatty acid and cholesterol than obese individuals, and several mechanisms have been proposed to explain this [21]. In the present case, the absolute, rather than the relative, level of n-3 LC-PUFA may be the determinant factor affecting gene transcription and, in the high lipid group, absolute levels of these fatty acids might have been sufficiently high to repress cholesterol biosynthesis genes,

even at lower relative n-3 LC-PUFA contents (i.e., group HL). This hypothesis is supported by the RT-qPCR analysis comparing the families with regards to lipid level, HL/LL and HH/LH. In the HL/LL comparison, contrasting absolute n-3 LC-PUFA levels of 427 *versus* 363 mg/100g flesh, there was down-regulation of both *ipi* and *srebp2* (-3.95 and -2.09, respectively), whereas comparison of the families HH/LH, containing 554 *versus* 468 mg/100g flesh, showed no difference in the expression of the genes. Similarly, genes involved in lipoprotein metabolism, which are also regulated by LC-PUFA through different mechanisms [20], also showed more significant changes when comparing fatter and leaner salmon with lower LC-PUFA levels, indicating that a similar regulatory mechanism might occur. Therefore, the present study is consistent with previous work identifying cholesterol and lipoprotein metabolism as pathways significantly and differentially affected by n-3 LC-PUFA depending on flesh adiposity [8].

### **Effects of total lipid level on lipid metabolism**

Lipid level significantly affected expression of lipid metabolism genes, although effects were still relatively small (8% of all genes assigned to a biological function category). A noteworthy result was the down-regulation of *elovl2* (confirmed by RT-qPCR) in salmon presenting higher flesh lipid, independent of LC-PUFA content. Elov12 has substrate specificity towards LC-PUFA and is highly responsive to dietary n-3 LC-PUFA levels in salmon [22]. However, the expression of this gene is often co-ordinately regulated with other genes of LC-PUFA biosynthesis, such as  $\Delta 5fad$  and  $\Delta 6fad$  [9], which was not the case here. Hence, the biological significance of this result is not clear and may indicate other roles of *elovl2* in lipid metabolism. For instance, an association between overexpression of *elovl2* and enhanced triacylglycerol synthesis and lipid droplet accumulation, as well as induction of PPAR $\gamma$  target genes, was shown in mouse preadipocyte cell lines [23]. In addition, *elovl2* was up-regulated in the liver transcriptome of rats with nephrotic syndrome, a condition

characterized by hyperlipidemia [24]. *Elovl2* was only recently characterized in salmon [22], and this is the first indication of an association between its expression and lipid accumulation in a non-mammalian vertebrate, with results suggesting that increased lipid level in salmon flesh repressed *elovl2* expression independent of n-3 LC-PUFA level although this requires further investigation. Another gene down-regulated at higher lipid levels was a mitochondrial acyl carrier protein, involved in acyl transfer steps, including roles in fatty acid synthesis and functioning of the electron transport chain [25], which could conceptually be responding to similar regulatory mechanisms affecting *elovl2*. In contrast, stearoyl-CoA desaturase, responsible for the synthesis of monounsaturated fatty acids from saturated precursors, was up-regulated in salmon with higher flesh lipid levels. This gene was positively correlated with fat accumulation in bovine skeletal muscle [26], consistent with up-regulation in salmon families with increased fat stores.

#### **Possible association between flesh n-3 LC-PUFA contents and immune response**

The predominance of immune response genes responding to total lipid level and, particularly, n-3 LC-PUFA contents in salmon flesh was unexpected. This was a true over-representation as GO enrichment analysis enabled identification of several GO terms related to regulation of immune and inflammatory responses in relation to the total lipid factor. However, as mentioned above, the transcriptomic comparison, although balanced for total lipid, was not balanced for viral disease resistance (specifically IPN in this case) and, as a consequence, higher contrast between families was imposed on the high lipid group (families HL and HH) due to the fortuitous selection of family HH presenting a much higher viral resistance EBV. Nonetheless, if family HH biased the results of the two-way ANOVA we would expect a preponderance of immune-related genes to occur only when comparing these two families, presenting higher and lower flesh n-3 LC-PUFA contents at the higher lipid level. In order to assess this, t-tests were performed comparing separately the higher versus lower n-3 LC-

PUFA families at each total lipid level, i.e., LH/LL and HH/HL. A Venn diagram contrasting the two t-test significant lists was then performed and when analyzing the genes that were similarly affected by n-3 LC-PUFA contents at both higher and lower total lipid level, a similar preponderance (33%) of immune response genes was observed (Additional file 4). Finally, examination of the fold changes of immune-related genes, indicating magnitude of effects, between families with higher and lower contents of n-3 LC-PUFA at either higher or lower total lipid levels (Tables 2 and 5), showed no clear evidence of the effect being more marked for the high lipid comparison, which is what would be expected if results were caused simply by inclusion of family HH in the transcriptomic analysis.

Hence, there is evidence to suggest that there may be some correlation between flesh n-3 LC-PUFA contents and immune response in the families analysed. An anti-inflammatory role of n-3 LC-PUFA is well established in mammals and fish [27-29]. Immune cells are typically rich in arachidonic acid (ARA), the precursor for eicosanoids with a pro-inflammatory action, whereas EPA and DHA give rise to eicosanoids that are less biologically active, as well as to resolvins and protectins presenting anti-inflammatory properties [30]. Higher incorporation of n-3 LC-PUFA in biological membranes of immune cells can modulate immune responses in several ways [reviewed in 15,30-33]. They alter the production of inflammatory eicosanoid mediators of which they are precursors, directly affect the organization and properties of the immune cell membranes with effects on signalling pathways, phagocytic capacity and antigen presenting capability, and activate transcription of various genes involved in inflammatory responses. Therefore, families with higher tissue levels of n-3 LC-PUFA may show differential expression of immune response and inflammation-related genes, as well as of genes involved in signalling and regulation of transcription (as observed in the present study). Furthermore, although liver is chiefly a metabolic organ, it has other physiological functions

including removal of pathogens and antigens from the blood and modulation of immune responses, as well as the production of inflammatory mediators [34,35].

Related to the above, microarray analysis revealed the presence of several genes that intervene in eicosanoid synthesis and metabolism including phospholipase A<sub>2</sub> (*pla2*), arachidonate 5-lipoxygenase (*alox5*), thromboxane-A synthase (*thas*), prostaglandin I<sub>2</sub> synthase (*ptgis*) and 15-hydroxyprostaglandin dehydrogenase [36]. However, RT-qPCR only confirmed up-regulation of hepatic *alox5* in families presenting higher flesh n-3 LC-PUFA and, given that *alox5* acts on LC-PUFA of both n-3 and n-6 series and that ARA levels generally accompanied the n-3 LC-PUFA phenotype (Table 1), it cannot be ascertained whether this transcript was responding to higher levels of membrane ARA or EPA and hence if it would result in increased pro-inflammatory 4-series, or less potent 5-series, leukotrienes [37].

The immune response genes whose expression was correlated with 'n-3 LC-PUFA' are mainly involved in the modulation of inflammatory processes and innate immune response to pathogens, which are particularly important in fish species and that can be easily compromised in aquaculture conditions [38]. We could speculate that the changes in expression may give enhanced protection from inflammation or pathological conditions in fish with higher n-3 LC-PUFA in their tissues. Up-regulation associated with high flesh n-3 LC-PUFA was noted in expression of NACHT domain containing protein, tripartite motif-containing protein 25 (*trim25*), c-c motif chemokine 13 precursor (*ccl13*), leukocyte cell-derived chemotaxin 2 precursor (*lect2*), tissue factor pathway inhibitor a, pentraxin and cathepsin K. In contrast, down-regulation in the high n-3 LC-PUFA families was observed for MHC class I (mostly in the high total lipid group), myelin and lymphocyte protein (*mal*). NACHT domain containing proteins are pathogen-sensing molecules (recognizing intracellular pathogen-associated molecular patterns – PAMPs) implicated in early host

defence, inflammation and innate immune signalling pathways in mammals [39], by activating transcription of MHC class II and the apoptotic pathway. The *trim25* protein is involved in antiviral innate immune responses through activation of signalling pathways leading to production of interferons and in teleost cells TRIM genes are induced in response to viral infections [40,41]. The *ccl13* (also known as monocyte chemotactic protein 4) and *lect2* proteins are both involved in inflammation, having roles in attracting monocytes and T lymphocytes in tissues exposed to exogenous pathogens, and neutrophil chemotactic function [42,43]. Expression of *lect2* was increased in fish liver and spleen after bacterial infections [43]. Tissue factor pathway inhibitor inhibits the initial reactions of the blood coagulation cascade and modulates cell proliferation, and may protect vascular tissue in inflammatory conditions in mammals [44]. Cathepsin K mediates immune responses in cells, having a critical role in signalling events proximal to the Toll-like receptor 9 (TLR9) that has a fundamental role in pathogen recognition (recognizing PAMPs) and activation of mammalian innate immunity [45]. Finally, pentraxins are pattern recognition proteins of the innate immune system that play a role in the acute phase response, activating complement pathways to clear pathogens in both mammals and fish [46,47]. In this case, up-regulation of pentraxin in salmon with higher n-3 LC-PUFA in their flesh was only observed with high lipid levels. Similarly, down-regulation of the MHC class I transcript was observed only in the high lipid group. In mammalian studies, high LC-PUFA contents (EPA, DHA and ARA) reduced cell surface expression of MHC I, decreasing antigen presentation and altering T-cell signalling [34,35]. Therefore, the high IPN resistance genotype observed in family HH in later genetic evaluations of the families could potentially involve effects on both the complement pathway and T-cell mediated immunity, and involve co- or post-translational modification of proteins by N-linked glycosylation through up-regulation of dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 (Table 2; [48]). Given the high economic impact of IPN

in salmonid culture, identification of genes potentially involved in the progression of the disease using transcriptomic approaches is already in progress [49]. Finally, down-regulation of *mal*, associated with T-cell differentiation and signal transduction [50], was observed at higher n-3 LC-PUFA levels.

As mentioned above, several immune response-related genes were also affected by the total lipid factor with results validated by RT-qPCR. However, we cannot exclude the possibility that this results from the strong correlation between total lipid levels and absolute LC-PUFA contents, which makes it difficult to dissociate both factors.

## **Conclusions**

It has been demonstrated earlier that LC-PUFA flesh content is a highly heritable trait [7], but the present study has shown that the underlying mechanisms do not appear to involve changes in the expression of lipid metabolism genes, including the LC-PUFA biosynthesis pathway. Other possible mechanisms, such as alleles with different biological activity, require investigation. The present study revealed an association between flesh adiposity and n-3 LC-PUFA in the regulation of cholesterol biosynthesis, which was down-regulated by higher n-3 LC-PUFA levels but only in the lean families. This response was not caused by dietary factors, given that the fish were all fed the same VO-based diet, and is most likely explained by variation in tissue n-3 LC-PUFA levels, regulating transcription of cholesterol metabolism genes through *srebp2*. Furthermore, the transcriptional repression of these genes may be sensitive to the absolute levels of these fatty acids in the tissues, which could explain the lack of regulation when comparing the families containing higher flesh lipid levels. It is likely that n-3 LC-PUFA exert similar roles in regulation of gene expression in fish as in mammals and, furthermore, fish might be a useful model to study important relationships between genetics, diet, adiposity/obesity and lipoprotein/cholesterol metabolism. However, unexpected differences were found in the expression of genes implicated in the modulation of

inflammatory processes and innate immune response between families differing in lipid composition, both in terms of total lipid level and, particularly, n-3 LC-PUFA contents. Although the evidence is generally circumstantial it is important to clarify this association if flesh n-3 LC-PUFA level is included as a trait for genetic selection in Atlantic salmon breeding programmes. If such a relationship is confirmed, the data suggest that the underlying mechanism might involve anti-inflammatory actions of tissue n-3 LC-PUFA on the eicosanoid biosynthesis pathway (particularly affecting the lipoxygenase pathway), although direct effects through regulation of transcription of immune genes or more indirectly through changes in architecture and properties of immune cell membranes are also possible.

## **Methods**

### **Feeding trial and sampling**

Fifty full-sib families selected from the 200 broodstock families of the Landcatch Natural Selection (LNS) Atlantic salmon breeding program (2005-strip year-group) were specifically selected for the feeding trial. On the basis of parental genetic evaluations, 25 high flesh lipid contrasting with 25 low flesh lipid families were identified, and 35 fish (initial weight, ~100 g) from each family were transferred and grown in communal seawater pens (Marine Harvest, Ardnish, Scotland). All fish were tagged with electronic transponders (PIT tags) to allow family identification while rearing in a common environment. After acclimation, the fish were grown for 12 weeks on the same low FM/high VO diet (Nutreco ARC, Stavanger, Norway) containing 25 % FM and 44 % plant meals and a VO blend including rapeseed oil/palm oil/camelina oil (2.5:1.5:1). At the end of the trial (378 g average weight), flesh samples (Norwegian Quality Cut) were collected, frozen on dry ice and stored at -20 °C until lipid analysis. Liver samples were also taken and stored at -70 °C for subsequent molecular analyses.

### **Lipid analysis and choice of families for transcriptomic comparisons**

The 50 selected families were screened for their ability to retain and/or synthesize n-3 LC-PUFA when fed a low FM/high VO diet. De-boned and skinned flesh samples were combined into 3 pools per family for lipid analysis. Total lipids were extracted and determined gravimetrically from 1-2 g of pooled flesh [51]. Fatty acid methyl esters (FAME) were prepared by acid-catalyzed transesterification of total lipids [52]. Following purification, FAME were separated and quantified by gas-liquid chromatography as described in [9]. These data were used to select four families for transcriptomic analysis: two with equivalent high levels of lipid 'H', and two with equivalent low levels of lipid 'L'. Within each level of total lipid, two families with significantly contrasting ( $p < 0.05$  on Student's t-test; Graphpad Prism™, version 4.0, Graphpad Software, San Diego, CA) relative n-3 LC-PUFA levels (similarly termed H and L) were identified (Table 1).

#### **RNA extraction and purification**

Hepatic tissue (200 mg) from ten individuals per family was rapidly homogenized in 2 ml TRI Reagent (Ambion, Applied Biosystems, Warrington, U.K.). Total RNA was isolated, following manufacturer's instructions, and RNA quality and quantity was assessed by gel electrophoresis and spectrophotometry (NanoDrop ND-1000, Thermo Scientific, Wilmington, U.S.A.), respectively. Equal amounts (50 µg) of total RNA were pooled from two individuals to produce five biological replicates per family, which were further purified by mini spin-column purification (RNeasy Mini Kit, Qiagen, Crawly, U.K.).

#### **Microarray hybridization and analysis**

A custom-made Atlantic salmon oligoarray with 44K features per array on a four-array-per-slide format (Agilent Technologies, Cheshire, U.K.), with experimental features printed singly was used; described more fully in [53]. The probes were co-designed at the Institute of Aquaculture, University of Stirling, U.K. and Nofima, Norway, with array design available in the EBI ArrayExpress database (<http://www.ebi.ac.uk/arrayexpress/arrays/browse.html>)

under accession number A-MEXP-2065. The features were mainly derived from a core set of Atlantic salmon Unigenes (NCBI) supplemented with other unique cDNAs derived from Genbank and the Atlantic Salmon Gene Index

(<http://compbio.dfci.harvard.edu/tgi/tgipage.html>). Probe annotations were derived from Blastx comparisons across four protein databases, detailed elsewhere [54]. The entire experiment comprised 20 hybridizations (5 slides): 4 groups (families) × 5 biological replicates (pools of 2 individuals each).

Indirect labelling was employed in preparing the microarray targets, as described in detail previously [8]. Antisense amplified RNA (aRNA) was produced from 500 ng of each total RNA purification reaction using the Amino Allyl MessageAmp™ II aRNA Amplification Kit (Ambion, Applied Biosystems), following the manufacturer's methodology followed by Cy3 or Cy5 fluor (PA23001 or PA25001, GE HealthCare) incorporation through a dye-coupling reaction.

The hybridizations were performed using SureHyb hybridisation chambers (Agilent) in a DNA Microarray Hybridisation Oven (Agilent). Sample order was semi-randomized, with one replicate per experimental group being loaded into each slide. Each biological replicate pool was co-hybridized in a two-dye experiment with a single pooled reference sample. This pooled reference comprised equal quantities of aRNA from all 20 biological replicate pools. Microarray manufacturer's instructions were followed. Briefly, for each hybridization, 825 ng of Cy3-labelled experimental biological replicate and Cy5-labelled reference pool were combined. A fragmentation master mix containing 10× blocking agent (Agilent), 25× fragmentation buffer (Agilent) and nuclease-free water, was dispensed into the Cy-dyes mix. After incubating in the dark at 60 °C for 30 mins, 2× GE Hybridization buffer (pre-heated to 37 °C; Agilent) was added, contents gently mixed, spun at 16K g for 1 min and finally kept on ice until loaded onto the microarray slides. Hybridization was carried out in the oven

rotator (Agilent) at 65 °C and 10 rpm for 17 h. Post-hybridization washes were carried out in EasyDip™ Slide staining containers (Canemco Inc., Quebec, Canada). After disassembling the array-gasket sandwiches submersed in wash buffer 1 (Agilent) at room temperature, the microarray slides were incubated in wash buffer 1 for 1 min at 31 °C in a Stuart Orbital Incubator S150 rotating at 150 rpm, and then a further 1 min at 31 °C at 150 rpm in wash buffer 2 (Agilent). A final dip in wash buffer 2 at room temperature was performed, after which the slides were dried by centrifugation (500 xg for 6 mins) and kept in a desiccator and in the dark until scanned, the same day.

Scanning was performed at 5 µm resolution using an Axon GenePix 4200AL Scanner (MDS Analytical Technologies, Wokingham, Berkshire, U.K.). Laser power was kept constant (50 %) and the “auto PMT” function within the acquisition software (v.4) was enabled to adjust PMT for each channel such that less than 0.1 % of features were saturated and that the mean intensity ratio of the Cy3 and Cy5 signals was close to one. Agilent Feature Extraction Software (v 9.5) was used to identify features and extract fluorescence intensity values from the resultant TIF images. Analysis of the intensity values was performed in the GeneSpring GX version 11 analysis platform (Agilent Technologies, Wokingham, Berkshire, U.K.). All intensity values <0.1 were set to equal 0.1 followed by a Lowess normalization. After removing control features, four quality filtering steps were carried out sequentially using a range of quality control metrics produced by the Agilent Feature Extraction software to remove features that were saturated, non uniform, population outliers and spots non-significantly different from background. This gave a final list of 32,566 probes that were eligible for statistical analysis. Experimental annotation complied fully with minimum information about a microarray experiment (MIAME) guidelines [55]. The experimental hybridizations and further methodological details are archived on the EBI ArrayExpress database under accession number E-TABM-1204.

Normalized and quality-filtered fluorescence intensity data was analysed in GeneSpring GX v11 by two-way ANOVA, which examined the explanatory power of the variables ‘total lipid’ and ‘n-3 LC-PUFA’ and the interaction between the two, at a significance level of 0.05 and intensity ratio (i.e., fold change) cut-off of 1.2. Two sets of analysis were performed, with or without Benjamini-Hochberg multiple testing correction. In the set with multiple testing correction, GO enrichment analysis was performed at a significance level of 0.05.

### **RT-qPCR**

Expression of selected genes found by microarray analysis to be significantly affected by either ‘total lipid’ or ‘n-3 LC-PUFA’ content was quantified by RT-qPCR. In addition, the expression of two fatty acyl desaturases (*Δ5fad* and *Δ6fad*) and one elongase (*elovl2*) that are typically responsive to dietary n-3 LC-PUFA was determined. Primers were designed using Primer3 software ([http://biotools.umassmed.edu/bioapps/primer3\\_www.cgi](http://biotools.umassmed.edu/bioapps/primer3_www.cgi)) (Table 7). Two reference genes, elongation factor-1 $\alpha$  (*elf-1 $\alpha$* ) and  *$\beta$ -actin*, were also quantified.

For RT-qPCR, 2  $\mu$ g of column-purified total RNA per sample was reverse transcribed into cDNA using the High-Capacity cDNA RT kit (Applied Biosystems, Paisley, U.K.), following manufacturer’s instructions, but using a mixture of the random primers (1.5  $\mu$ l as supplied) and anchored oligo-dT (0.5  $\mu$ l at 400 ng/ $\mu$ l, Eurofins MWG Operon, Ebersberg, Germany). Negative controls (containing no enzyme) were performed to check for genomic DNA contamination. A similar amount of cDNA was pooled from all samples and the remaining cDNA was then diluted 20-fold with water. RT-qPCR analysis used relative quantification with the amplification efficiency of the primer pairs being assessed by serial dilutions of the cDNA pool. Amplifications were carried out in duplicate (Quanta, Techne, Cambridge, U.K.) in a final volume of 20  $\mu$ l containing 5  $\mu$ l or 2  $\mu$ l (for more highly expressed genes) diluted (1/20) cDNA, 0.5  $\mu$ M of each primer (0.4  $\mu$ M for *lect2*) and 10  $\mu$ l Absolute<sup>TM</sup> QPCR SYBR<sup>®</sup> Green mix (ABgene). Amplifications were carried out with a systematic

negative control (NTC-non template control, containing no cDNA). The RT-qPCR profiles contained an initial activation step at 95 °C for 15 min, followed by 30 to 40 cycles: 15 s at 95 °C, 15 s at the specific primer pair annealing temperature ( $T_a$ ; Table 7) and 15 s at 72 °C. After the amplification phase, a melt curve of 0.5 °C increments from 75 °C to 90 °C was performed, enabling confirmation of the amplification of a single product in each reaction. Non-occurrence of primer-dimer formation in the NTC was verified. RT-qPCR product sizes and presence of single bands were checked by agarose gel electrophoresis. Additionally, sequencing of amplicons corresponding to new primer designs enabled the confirmation of identities and presence of single sequences for all genes except for *trim25*, as the sequencing result was of insufficient quality to conclude on the presence of a single gene product, and *lrp1*, for which results were indicative of quantification of a highly similar, recently duplicated, gene.

Results were analyzed by the  $\Delta\Delta C_t$  method using the relative expression software tool (REST 2009, <http://www.gene-quantification.info/>), which employs a pair wise fixed reallocation randomization test (10,000 randomizations) with efficiency correction [56], to determine the statistical significance of expression ratios (or gene expression fold-changes) between two treatments.

### **Genetic evaluations of traits used in the salmon breeding program**

Parental evaluations were confirmed by subsequent analysis of family sibs (at harvest weight, some 1 year after the present study) for a range of traits upon which the breeding program families are under active selection including flesh lipid composition parameters (total lipid) as well as EBVs for weight at harvest, precocious maturation, flesh colour, sealice resistance and resistance to a viral infection (IPN).

### **Competing Interests**

The authors declare that they have no competing interests.

### **Author's contributions**

SM performed laboratory analyses and data analysis. DRG was responsible for family selection. JBT supported the microarray analysis. SM wrote the first draft of the manuscript, followed by contributions from remaining authors. SM, JBT and DRT planned and coordinated the research. DRG, JGB and DRT were project leaders. All authors read and approved the final manuscript.

### **Acknowledgements**

This study was funded by the EU FP6 IP "AQUAMAX" (Sustainable Aquafeeds to Maximise the Health Benefits of Farmed Fish for Consumers; 016249-2). SM was supported by Fundação para a Ciência e a Tecnologia, Portugal (SFRH/BPD/64679/2009). Technical assistance from Jackie Ireland in microarray hybridizations is deeply appreciated.

### **Additional files**

Additional file 1: Relationship between total lipid level and n-3 LC-PUFA content.

Additional file 2: Gene Ontology terms showing significant enrichment in the list of features affected by the 'total lipid' factor.

Additional file 3: Distribution of IPN resistance scores in relation to flesh lipid phenotypes.

Additional file 4: Genes similarly regulated in pair-wise comparisons of families containing H and L n-3 LC-PUFA flesh contents, at each one of the total lipid levels.

### **References**

1. FAO: *The State of World Fisheries and Aquaculture 2008*. Rome: Food and Agriculture Organization of the United Nations; 2009.
2. Tacon AGJ, Metian M: **Global overview on the use of fish meal and fish oil in industrially compounded aquafeeds: Trends and future prospects**. *Aquaculture* 2008, **285**:146-158.

3. Calder PC, Yaqoob P: **Omega-3 polyunsaturated fatty acids and human health outcomes.** *BioFactors* 2009, **35**:266-272.
4. Menoyo D, López-Bote CJ, Obach A, Bautista JM: **Effect of dietary fish oil substitution with linseed oil on the performance, tissue fatty acid profile, metabolism, and oxidative stability of Atlantic salmon.** *J Anim Sci* 2005, **83**:2853-2862.
5. Gjedrem T, Baranski, M: *Selective Breeding in Aquaculture: an Introduction* [Series: Reviews: Methods and Technologies in Fish Biology and Fisheries, Vol. 10]. London: Springer Science + Business Media B.V.; 2009.
6. Schlechtriem C, Bron JE, Tocher DR: **Inter-individual variation in total lipid fatty acid compositions of flesh of Atlantic salmon smolts fed diets containing fish oil or vegetable oil.** *Aquaculture Res* 2007, **38**:1045-1055.
7. Leaver MJ, Taggart JB, Villeneuve L, Bron JE, Guy DR, Bishop SC, Houston RD, Matika O, Tocher DR: **Heritability and mechanisms of n-3 long chain polyunsaturated fatty acid deposition in the flesh of Atlantic salmon.** *Comp Biochem Physiol Part D Genomics Proteomics* 2011, **6**:62-69.
8. Morais S, Pratoomyot J, Torstensen BE, Taggart JB, Guy DR, Bell JG, Tocher DR: **Diet × genotype interactions in hepatic cholesterol and lipoprotein metabolism in Atlantic salmon (*Salmo salar*) in response to replacement of dietary fish oil with vegetable oil.** *Br J Nutr* 2011, **106**: 1457-1469.
9. Morais S, Pratoomyot J, Taggart JB, Bron JE, Guy DR, Bell JG, Tocher DR: **Genotype-specific responses in Atlantic salmon (*Salmo salar*) subject to dietary fish oil replacement by vegetable oil: a liver transcriptomic analysis.** *BMC Genomics* 2011, **12**:255.

10. LeBlanc F, Laflamme M, Gagné N: **Genetic markers of the immune response of Atlantic salmon (*Salmo salar*) to infectious salmon anemia virus (ISAV).** *Fish Shellfish Immunol* 2010, **29**:217-232.
11. Leaver MJ, Villeneuve LA, Obach A, Jensen L, Bron JE, Tocher DR, Taggart JB: **Functional genomics reveals increases in cholesterol biosynthetic genes and highly unsaturated fatty acid biosynthesis after dietary substitution of fish oil with vegetable oils in Atlantic salmon (*Salmo salar*).** *BMC Genomics* 2008, **9**:299.
12. Houston RD, Haley CS, Hamilton A, Guy DR, Tinch AE, Taggart JB, McAndrew BJ, Bishop SC: **Major quantitative trait loci affect resistance to infectious pancreatic necrosis in Atlantic salmon (*Salmo salar*).** *Genetics* 2008, **178**:1109-1115.
13. Zheng X, Tocher DR, Dickson CA, Bell JG, Teale AJ: **Effects of diets containing vegetable oil on expression of genes involved in highly unsaturated fatty acid biosynthesis in liver of Atlantic salmon (*Salmo salar*).** *Aquaculture* 2004, **236**:467-483.
14. Zheng X, Torstensen BE, Tocher DR, Dick JR, Henderson RJ, Bell JG: **Environmental and dietary influences on highly unsaturated fatty acid biosynthesis and expression of fatty acyl desaturase and elongase genes in liver of Atlantic salmon (*Salmo salar*).** *Biochim Biophys Acta* 2005, **1734**:13-24.
15. Galli C, Calder PC: **Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review.** *Ann Nutr Metab* 2009, **55**:123-139.
16. Kolditz CI, Paboeuf G, Borthaire M, Esquerré D, SanCristobal M, Lefèvre F, Médale F: **Changes induced by dietary energy intake and divergent selection for muscle fat content in rainbow trout (*Oncorhynchus mykiss*), assessed by transcriptome and proteome analysis of the liver.** *BMC Genomics* 2008, **9**:506.
17. Watts JL, Browse J: **Genetic dissection of polyunsaturated fatty acid synthesis in *Caenorhabditis elegans*.** *Proc Natl Acad Sci U S A* 2002, **99**:5854-5859.

18. Sakakura Y, Shimano H, Sone H, Takahashi A, Inoue K, Toyoshima H, Suzuki S, Yamada N: **Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis.** *Biochem Biophys Res Commun* 2001, **286**:176-183.
19. Jump DB, Botolin D, Wang Y, Xu J, Christian B, Demeure O: **Fatty acid regulation of hepatic gene transcription.** *J Nutr* 2005, **135**:2503-2506.
20. Sampath H, Ntambi JM: **Polyunsaturated fatty acid regulation of genes of lipid metabolism.** *Annu Rev Nutr* 2005, **25**:317-340.
21. Flock MR, Green MH, Kris-Etherton PM: **Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol.** *Adv Nutr* 2011, **2**:261-274.
22. Morais S, Monroig O, Zheng X, Leaver MJ, Tocher DR: **Highly unsaturated fatty acid synthesis in Atlantic salmon: characterization of ELOVL5- and ELOVL2-like elongases.** *Mar Biotechnol* 2009, **1**:627-639.
23. Kobayashi T, Zadavec D, Jacobsson A: **ELOVL2 overexpression enhances triacylglycerol synthesis in 3T3-L1 and F442A cells.** *FEBS Lett* 2007, **581**:3157-3163.
24. Zhou Y, Zhang X, Chen L, Wu J, Dang H, Wei M, Fan Y, Zhang Y, Zhu Y, Wang N, Breyer MD, Guan Y: **Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats.** *Am J Physiol Renal Physiol* 2008, **295**:F662-671.
25. Feng D, Witkowski A, Smith S: **Down-regulation of mitochondrial acyl carrier protein in mammalian cells compromises protein lipoylation and respiratory complex I and results in cell death.** *J Biol Chem* 2009, **284**:11436-11445.
26. Jiang Z, Michal JJ, Tobey DJ, Daniels TF, Rule DC, Macneil MD: **Significant associations of stearoyl-CoA desaturase (SCD1) gene with fat deposition and composition in skeletal muscle.** *Int J Biol Sci* 2008, **4**:345-351.

27. Montero D, Grasso V, Izquierdo MS, Ganga R, Real F, Tort L, Caballero MJ, Acosta F: **Total substitution of fish oil by vegetable oils in gilthead sea bream (*Sparus aurata*) diets: effects on hepatic Mx expression and some immune parameters.** *Fish Shellfish Immunol* 2008, **24**:147-155.
28. Oxley A, Jolly C, Eide T, Jordal AE, Svardal A, Olsen RE: **The combined impact of plant-derived dietary ingredients and acute stress on the intestinal arachidonic acid cascade in Atlantic salmon (*Salmo salar*).** *Br J Nutr* 2010, **103**:851-861.
29. Estensoro I, Benedito-Palos L, Palenzuela O, Kaushik S, Sitjà-Bobadilla A, Pérez-Sánchez J: **The nutritional background of the host alters the disease course in a fish–myxosporean system.** *Vet Parasitol* 2011, **175**:141-150.
30. Yaqoob P: **Mechanisms underlying the immunomodulatory effects of n-3 PUFA.** *Proc Nutr Soc* 2010, **69**:311-315.
31. Calder PC: **Dietary modification of inflammation with lipids.** *Proc Nutr Soc* 2002, **61**:345-358.
32. Shaikh SR, Edidin M: **Polyunsaturated fatty acids, membrane organization, T cells, and antigen presentation.** *Am J Clin Nutr* 2006, **84**:1277-1289.
33. Yaqoob P, Calder PC: **Fatty acids and immune function: new insights into mechanisms.** *Br J Nutr* 2007, **98 Suppl 1**:S41-45.
34. Kmiec Z: **Cooperation of liver cells in health and disease.** *Adv Anat Embryol Cell Biol* 2001, **161**:III-XIII, 1-151.
35. Knolle PA, Gerken G: **Local control of the immune response in the liver.** *Immunol Rev* 2000, **174**:21-34.
36. Smith WL: **The eicosanoids and their biochemical mechanisms of action.** *Biochem J* 1989, **259**:315-324.

37. Lee TH, Mencia-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF: **Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils.** *J Clin Invest* 1984, **74**:1922-1933.
38. Ellis AE: **Innate host defense mechanisms of fish against viruses and bacteria.** *Dev Comp Immunol* 2001, **25**:827-839.
39. Stein C, Caccamo M, Laird G, Leptin M: **Conservation and divergence of gene families encoding components of innate immune response systems in zebrafish.** *Genome Biol* 2007, **8**:R251.
40. Munir M: **TRIM proteins: another class of viral victims.** *Sci Signal* 2010, **3**:jc2.
41. van der Aa LM, Levraud JP, Yahmi M, Lauret E, Briolat V, Herbomel P, Benmansour A, Boudinot P: **A large new subset of TRIM genes highly diversified by duplication and positive selection in teleost fish.** *BMC Biol* 2009, **7**:7.
42. Ugucioni M, Loetscher P, Forssmann U, Dewald B, Li H, Lima SH, Li Y, Kreider B, Garotta G, Thelen M, Baggiolini M: **Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin.** *J Exp Med* 1996, **183**:2379-2384.
43. Li MY, Chen J, Shi YH: **Molecular cloning of leucocyte cell-derived chemotaxin-2 gene in croceine croaker (*Pseudosciaena crocea*).** *Fish Shellfish Immunol* 2008, **24**:252-256.
44. Kato H: **Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects.** *Arterioscler Thromb Vasc Biol* 2002, **22**:539-548.
45. Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P,

- Takayanagi H: **Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.** *Science* 2008, **319**:624-627.
46. Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A: **Pattern recognition by pentraxins.** *Adv Exp Med Biol* 2009, **653**:98-116.
47. Gísladóttir B, Guðmundsdóttir S, Brown L, Jonsson ZO, Magnadóttir B: **Isolation of two C-reactive protein homologues from cod (*Gadus morhua* L.) serum.** *Fish Shellfish Immunol* 2009, **26**:210-219.
48. Larkin A, Imperiali B: **The expanding horizons of asparagine-linked glycosylation.** *Biochemistry* 2011, **50**:4411-4426.
49. Cepeda V, Cofre C, González R, MacKenzie S, Vidal R: **Identification of genes involved in immune response of Atlantic salmon (*Salmo salar*) to IPN virus infection, using expressed sequence tag (EST) analysis.** *Aquaculture* 2011, **318**:54-60.
50. Alonso MA, Weissman, SM: **cDNA cloning and sequence of MAL, a hydrophobic protein associated with human T-cell differentiation.** *Proc Natl Acad Sci U S A* 1987, **84**:1997-2001.
51. Folch J, Lees M, Sloane-Stanley GH: **A simple method for the isolation and purification of total lipides from animal tissues.** *J Biol Chem* 1957, **226**:497-509.
52. Christie WW: *Lipid analysis.* Bridgewater: The Oily Press; 2003.
53. Tacchi L, Bron JE, Taggart JB, Secombes CJ, Bickerdike R, Adler MA, Takle H, Martin SAM: **2011 Multiple tissue transcriptomic responses to *Piscirickettsia salmonis* in Atlantic salmon (*Salmo salar*)** *Physiol Genomics* 2011, **43**:1241-1254.
54. Krasnov A, Timmerhaus G, Afanasyev S, Jørgensen S-M: **Development and assessment of oligonucleotide microarrays for Atlantic salmon (*Salmo salar* L.).** *Comp Biochem Physiol Part D Genomics Proteomics* 2011, **6**:31-38

55. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M: **Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.** *Nat Genet* 2001, **29**:365-371.
56. Pfaffl MW, Horgan GW, Dempfle L: **Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR.** *Nucleic Acids Res* 2002, **30**:e36.
57. Haugland O, Torgersen J, Syed M, Evensen O: **Expression profiles of inflammatory and immune-related genes in Atlantic salmon (*Salmo salar* L.) at early time post vaccination.** *Vaccine* 2005, **23**:5488-5499.
58. Todorčević M, Skugor S, Krasnov A, Ruyter B: **Gene expression profiles in Atlantic salmon adipose-derived stromo-vascular fraction during differentiation into adipocytes.** *BMC Genomics* 2010, **11**:39.
59. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: **Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.** *Genome Biology* 2002, **3**:34.1-34.11.

**Table 1 Lipid phenotypes of families chosen for molecular analysis.** Indicated are levels of total lipid (g/100g flesh, wet weight), and relative and absolute contents of total n-3 LC-PUFA and of the n-6 LC-PUFA arachidonic acid (ARA) in the flesh (n=3 pools) of the 4 Atlantic salmon families used in the transcriptomic analysis. Asterisks signify significant differences between the two families with the same total lipid content.

| Family | Total Lipid<br>(g/100g flesh) | n-3 LC-PUFA                                  |                             | ARA  |                             |
|--------|-------------------------------|--|-----------------------------|--|-----------------------------|
|        |                               | Relative<br>( $\mu\text{g}/\text{mg}$ lipid) | Absolute<br>(mg/100g flesh) | Relative<br>( $\mu\text{g}/\text{mg}$ lipid) | Absolute<br>(mg/100g flesh) |
| LL     | 3.5 $\pm$ 0.4                 | 105.1 $\pm$ 3.8 *                            | 363.0 $\pm$ 30.3            | 3.45 $\pm$ 0.13 *                            | 11.93 $\pm$ 1.00            |
| LH     | 3.5 $\pm$ 0.7                 | 133.8 $\pm$ 4.8 *                            | 468.0 $\pm$ 92.9            | 4.25 $\pm$ 0.06 *                            | 14.87 $\pm$ 2.94            |
| HL     | 5.1 $\pm$ 0.8                 | 83.7 $\pm$ 14.0 *                            | 426.9 $\pm$ 103.2           | 2.70 $\pm$ 0.53                              | 13.81 $\pm$ 3.80            |
| HH     | 5.0 $\pm$ 0.7                 | 112.0 $\pm$ 7.9 *                            | 554.3 $\pm$ 50.7            | 3.67 $\pm$ 0.63                              | 18.04 $\pm$ 2.09            |

**Table 2 Liver transcripts differentially expressed when examining the explanatory power of the factor 'n-3 LC-PUFA' content in flesh of four families of Atlantic salmon fed the same low FM/high VO diet.** Results were obtained by two-way ANOVA analysis ( $p < 0.05$ ; fold change cut-off of 1.2) with Benjamini-Hochberg multiple testing correction. Transcripts (43 probes; 12% unknowns) are arranged by categories of biological function and, within these, by p-value. Indicated are also the probe names and the expression ratio determined separately between families with high vs low n-3 LC-PUFA contents, for each total lipid level. Percentages of distribution of genes within each category do not include non-annotated probes, those representing the same gene or with a miscellaneous function.

| Probe name                                       | Gene  | High/Low LC-PUFA |                 | p-value |
|--|---|------------------|-----------------|---------|
|  |   | L Lipid (LH/LL)  | H Lipid (HH/HL) |         |
| <b>Metabolism (21%)</b>                          |   |                  |                 |         |
| <i>Energy metabolism (4%)</i>                    |   |                  |                 |         |
| Ssa#S31995754                                    | Cytochrome c oxidase subunit 2  | 7.1              | - 1.0           | 0.0001  |
| <i>Protein and amino acid metabolism (13%)</i>   |   |                  |                 |         |
| Ssa#CB502423                                     | N-acetylated alpha-linked acidic dipeptidase-like 1   | 3.7              | 79.8            | 0.0011  |
| Ssa#STIR03710                                    | Proteasome subunit beta type-9 precursor  | - 14.9           | - 1.1           | 0.0026  |
| Ssa#S31993738_S                                  | Ubiquitin-conjugating enzyme E2   | - 3.3            | - 1.4           | 0.0188  |
| <i>Xenobiotic and oxidant metabolism (4%)</i>    |   |                  |                 |         |
| Ssa#S18892279                                    | Cytochrome P450 1A  | 1.8              | 1.4             | 0.0096  |
| Ssa#STIR00161_2                                  | Cytochrome P450 1A  | 1.9              | 1.4             | 0.0160  |
| Ssa#STIR00161_3                                  | Cytochrome P450 1A  | 2.5              | 1.8             | 0.0213  |
| Con_CANDS_13                                     | Cytochrome P450 1A  | 2.0              | 1.4             | 0.0494  |
| <b>Translation (8%)</b>                          |   |                  |                 |         |
| Ssa#STIR26031                                    | Mitochondrial 28S ribosomal protein S34   | - 11.1           | 1.5             | 0.0017  |
| Ssa#S18867312                                    | Ribonuclease UK114  | 1.4              | 1.4             | 0.0450  |
| <b>Regulation of transcription (17%)</b>         |   |                  |                 |         |
| Ssa#S35510106                                    | Zinc finger protein 367   | - 1.4            | 6.5             | 0.0026  |
| Omy#S18104058                                    | Zinc finger protein 235   | 4.1              | 2.3             | 0.0058  |
| Ssa#TC111702                                     | Reverse transcriptase-like protein  | - 1.3            | 4.6             | 0.0104  |
| Ssa#TC112002                                     | Retinoid X receptor beta  | 1.0              | - 19.1          | 0.0134  |
| <b>Signalling and protein modification (17%)</b> |   |                  |                 |         |
| Ssa#STIR15776                                    | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4                     | - 1.7            | 123.3           | 0.0000  |
| Ssa#STIR23530                                    | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4                     | - 1.9            | 115.6           | 0.0000  |
| Ssa#STIR03642                                    | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4                     | - 1.7            | 68.1            | 0.0000  |
| Ssa#STIR01857                                    | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4                     | - 1.5            | 125.5           | 0.0001  |
| Ssa#STIR31840                                    | Sphingomyelin phosphodiesterase acid transcript variant 1                                   | 2.1              | 2.3             | 0.0303  |
| Ssa#STIR07369                                    | RAF1 proto-oncogene serine/threonine-protein kinase   | 1.8              | 1.3             | 0.0343  |
| Ssa#S35552908                                    | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide | - 1.6            | - 2.1           | 0.0455  |

**Immune response (38%)**

|               |  |        |        |        |
|---------------|--|--------|--------|--------|
| Ssa#S35536179 | similar to novel NACHT domain containing protein               | 2.4    | 1.8    | 0.0026 |
| Ssa#S35516341 | Tripartite motif-containing protein 25 ( <i>trim25</i> )       | 5.2    | 6.7    | 0.0066 |
| Ssa#S30241035 | MHC class I  | - 1.3  | - 26.0 | 0.0079 |
| Ssa#STIR02298 | c-c motif chemokine 13 precursor ( <i>ccl13</i> )              | 4.4    | 3.0    | 0.0100 |
| Ssa#S35581943 | Myelin and lymphocyte protein ( <i>mal</i> )                   | - 22.2 | - 25.0 | 0.0100 |
| Ssa#KSS3969   | Leukocyte cell-derived chemotaxin 2 precursor ( <i>lect2</i> ) | 4.6    | 7.1    | 0.0134 |
| Ssa#STIR15577 | Tissue factor pathway inhibitor a                              | 22.3   | 1.7    | 0.0135 |
| Omy#S15332652 | Pentraxin  | - 1.1  | 199.4  | 0.0172 |
| Ssa#TC70262   | Cathepsin K  | 1.4    | 2.3    | 0.0279 |
| Ssa#S35558945 | Tripartite motif-containing protein 25 ( <i>trim25</i> )       | 4.8    | 6.5    | 0.0347 |

**Miscellaneous/unknown function**

|                 |  |       |       |        |
|-----------------|--|-------|-------|--------|
| Ssa#STIR09736   | Transmembrane protein 42   | 2.3   | 1.9   | 0.0009 |
| Ssa#S35519407   | Tetratricopeptide repeat protein 23                                    | 3.7   | 1.0   | 0.0011 |
| Ssa#STIR02307   | Family with sequence similarity member a (FAM36A)                      | 1.3   | 3.6   | 0.0026 |
| Omy#BX309274    | X-ray repair complementing defective repair in Chinese hamster cells 3 | - 1.0 | - 8.0 | 0.0100 |
| Ssa#STIR21287   | Solute carrier family 30 (zinc transporter) member 7                   | 2.1   | 1.5   | 0.0100 |
| Ssa#S35521859_S | Family with sequence similarity member a (FAM36A)                      | - 1.1 | 4.8   | 0.0358 |
| Ssa#S18842295   | Alveolin   | 1.7   | 4.6   | 0.0422 |

---

**Table 3 Liver transcripts differentially expressed when examining the explanatory power of the variable 'total lipid' level in flesh of four families of Atlantic salmon fed the same low FM/high VO diet.** Results were obtained by two-way ANOVA analysis ( $p < 0.05$ ; fold change cut-off of 1.2) with Benjamini-Hochberg multiple testing correction. Transcripts (109 probes; 18% unknowns) are arranged by categories of biological function and, within these, by p-value. Indicated are also the probe names and the expression ratio determined separately between families with high vs low total lipid level, for each n-3 LC-PUFA grouping. Percentages of distribution of genes within each category do not include non-annotated probes, those representing the same gene or with a miscellaneous function.

| Probe name   | Gene   | High/Low Lipid        |                       | p-value |
|--|--|-----------------------|-----------------------|---------|
|  |  | Lo LC-PUFA<br>(HL/LL) | Hi LC-PUFA<br>(HH/LH) |         |
| <b>Metabolism (30%)</b>  |  |                       |                       |         |
| <i>Lipid metabolism (8%)</i>   |  |                       |                       |         |
| Ssa#STIR02479  | Butyrophilin subfamily 2 member A2 precursor                 | 7.76                  | 1.23                  | 0.0001  |
| Ssa#STIR03356  | Acyl carrier protein, mitochondrial precursor                | - 5.17                | - 1.55                | 0.0004  |
| Ssa#STIR00151_3  | Polyunsaturated fatty acid elongase ( <i>elovl2</i> )        | - 1.40                | - 1.87                | 0.0190  |
| Ssa#STIR00151_2  | Polyunsaturated fatty acid elongase ( <i>elovl2</i> )        | - 1.28                | - 1.97                | 0.0238  |
| Con_CANDS_03   | Polyunsaturated fatty acid elongase ( <i>elovl2</i> )        | - 1.33                | - 1.82                | 0.0310  |
| Ssa#STIR24266  | Acyl carrier protein, mitochondrial precursor                | - 2.88                | - 1.52                | 0.0312  |
| Ssa#STIR21802  | Stearoyl-CoA desaturase                                      | 3.53                  | 3.17                  | 0.0324  |
| Ssa#STIR00151_4  | Polyunsaturated fatty acid elongase ( <i>elovl2</i> )        | - 1.41                | - 1.82                | 0.0393  |
| Ssa#S35501441_S  | Acyl carrier protein, mitochondrial precursor                | - 2.65                | - 1.44                | 0.0457  |
| Ssa#KSS4634  | Stearoyl-CoA desaturase                                      | 3.52                  | 2.82                  | 0.0486  |
| <i>Energy metabolism and generation of precursor metabolites (11%)</i> |  |                       |                       |         |
| Ssa#S31995754  | Cytochrome c oxidase subunit 2                               | 6.57                  | - 1.12                | 0.0002  |
| Ssa#STIR03496  | LYR motif-containing protein 5                               | 1.20                  | 1.48                  | 0.0233  |
| Ssa#STIR03740  | 6-Phosphogluconate dehydrogenase, decarboxylating            | 1.60                  | 1.93                  | 0.0238  |
| Ssa#TC106663   | Creatine kinase, testis isozyme                              | 1.76                  | 1.46                  | 0.0380  |
| Ssa#STIR19155  | NADH dehydrogenase iron-sulfur protein 7                     | 1.21                  | 2.30                  | 0.0409  |
| Ssa#STIR12872  | V-type ATPase B subunit                                      | - 1.19                | - 1.24                | 0.0419  |
| <i>Protein and amino acid metabolism (4%)</i>                          |  |                       |                       |         |
| Ssa#STIR03710  | Proteasome subunit beta type-9 precursor                     | 1.94                  | 25.52                 | 0.0001  |
| Ssa#S30294677  | Serine protease HTRA1 precursor (Serine protease 11)         | 3.42                  | 2.44                  | 0.0089  |
| <i>Carbohydrate metabolism (4%)</i>                                    |  |                       |                       |         |
| Ssa#TC106766   | Glycogenin   | 8.64                  | 1.67                  | 0.0093  |
| Ssa#S30290426  | Serine dehydratase-like                                      | 1.60                  | 1.72                  | 0.0393  |
| <i>Xenobiotic and oxidant metabolism (4%)</i>                          |  |                       |                       |         |
| Ssa#S35671757  | Extracellular superoxide dismutase                           | 2.18                  | 1.09                  | 0.0061  |
| Ssa#STIR25620  | Microsomal glutathione S-transferase 1                       | 2.45                  | 2.72                  | 0.0096  |
| Omy#S18159333  | Microsomal glutathione S-transferase 1                       | 2.47                  | 3.15                  | 0.0233  |
| <b>Transport (2%)</b>  |  |                       |                       |         |
| Ssa#S35599996  | ATPase, H <sup>+</sup> transporting, lysosomal, V1 subunit H | 45.10                 | 15.16                 | 0.0000  |

**Translation (4%)**

|               |   |      |       |        |
|---------------|---|------|-------|--------|
| Ssa#STIR26031 | Mitochondrial 28S ribosomal protein S34 | 1.19 | 19.22 | 0.0000 |
| Ssa#S30241612 | 39S ribosomal protein L16               | 1.30 | 1.51  | 0.0324 |

**Regulation of transcription (12%)**

|               |   |        |         |        |
|---------------|---|--------|---------|--------|
| Ssa#STIR06878 | Cytosolic iron-sulfur protein assembly 1                                    | - 1.16 | - 1.56  | 0.0106 |
| Ssa#TC112002  | Retinoid X receptor beta  | 1.20   | - 16.00 | 0.0254 |
| Omy#S15320037 | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a4 | - 1.97 | - 1.53  | 0.0324 |
| Ssa#CN181280  | alpha thalassaemia mental retardation X-linked protein                      | - 3.05 | - 6.90  | 0.0419 |
| Ssa#S35697153 | YLP motif containing 1  | - 1.49 | - 1.32  | 0.0428 |
| Ssa#S35486480 | Zinc finger protein 492   | - 1.08 | - 2.29  | 0.0452 |

**Signalling and protein modification (13%)**

|               |   |         |         |        |
|---------------|---|---------|---------|--------|
| Ssa#STIR15776 | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 | - 84.27 | 2.44    | 0.0000 |
| Ssa#STIR23530 | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 | - 83.34 | 2.60    | 0.0000 |
| Ssa#STIR03642 | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 | - 49.76 | 2.34    | 0.0001 |
| Ssa#STIR01857 | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 | - 74.19 | 2.51    | 0.0011 |
| Ssa#S35516167 | 14 kDa phosphohistidine phosphatase                                     | 1.57    | 1.34    | 0.0019 |
| Ssa#STIR11086 | Lunatic fringe  | - 5.47  | - 2.00  | 0.0154 |
| Ssa#S30263209 | HtrA serine peptidase 3   | 3.71    | 2.33    | 0.0154 |
| Ssa#STIR22920 | HCLS1-associated protein X-1  | 1.73    | 2.33    | 0.0390 |
| Ssa#S35701148 | Phosphatase and actin regulator 3                                       | - 1.52  | - 65.53 | 0.0404 |
| Omy#S15290792 | Serine/threonine-protein kinase PLK2                                    | 1.70    | 2.03    | 0.0468 |

**Immune response (29%)**

|                 |  |         |         |        |
|-----------------|--|---------|---------|--------|
| Ssa#STIR00130_4 | Complement factor H precursor ( <i>cfh</i> )                   | - 1.43  | - 1.67  | 0.0012 |
| Ssa#S35536179   | novel NACHT domain containing protein                          | - 1.89  | - 2.41  | 0.0013 |
| Ssa#S30241035   | MHC class I  | - 1.55  | - 30.59 | 0.0024 |
| Ssa#S35516341   | Tripartite motif-containing protein 25 ( <i>trim25</i> )       | - 5.64  | - 4.34  | 0.0125 |
| Ssa#S18834140   | Complement factor H precursor ( <i>cfh</i> )                   | - 1.34  | - 1.57  | 0.0131 |
| Omy#utu04b09    | Complement factor H precursor ( <i>cfh</i> )                   | - 1.56  | - 1.70  | 0.0134 |
| Ssa#STIR15577   | Tissue factor pathway inhibitor a                              | 21.03   | 1.59    | 0.0151 |
| Ssa#S35558236   | C-type lectin domain family 16, member A                       | 4.59    | 2.25    | 0.0190 |
| Ssa#STIR10409   | CD83 antigen precursor   | 1.98    | 1.68    | 0.0238 |
| Omy#S15332652   | Putative pentraxin   | - 1.33  | 159.84  | 0.0246 |
| Ssa#S35685271   | GTPase IMAP family member 7                                    | -168.44 | - 4.09  | 0.0263 |
| Ssa#S35551959   | Duodenase-1  | - 2.94  | - 2.77  | 0.0349 |
| Ssa#S35558945   | Tripartite motif-containing protein 25 ( <i>trim25</i> )       | - 5.74  | - 4.28  | 0.0373 |
| Ssa#S35685273   | Lactose-binding lectin l-2 precursor putative                  | 1.56    | 4.04    | 0.0380 |
| Ssa#S31977617   | Scavenger receptor cysteine-rich type 1 protein m130           | - 1.31  | - 2.05  | 0.0404 |
| Ssa#STIR04893   | Lactose-binding lectin l-2 precursor putative                  | 1.57    | 4.15    | 0.0419 |
| Ssa#S30264865   | Indoleamine-pyrrole 2,3-dioxygenase                            | 2.83    | 1.06    | 0.0444 |
| Ssa#S31981622   | Granzyme A   | - 5.31  | - 4.33  | 0.0444 |
| Ssa#S35685718   | CD83 antigen precursor   | 2.03    | 1.58    | 0.0462 |
| Ssa#KSS3969     | Leukocyte cell-derived chemotaxin 2 precursor ( <i>lect2</i> ) | 3.16    | 4.86    | 0.0486 |

**Structural proteins (10%)**

|               |  |          |          |        |
|---------------|--|----------|----------|--------|
| Ssa#STIR03004 | Troponin I, slow skeletal muscle                       | - 202.28 | - 135.03 | 0.0000 |
| Ssa#CK891024  | Vitelline envelope protein gamma                       | 1.07     | - 15.43  | 0.0002 |
| Ssa#STIR02053 | Troponin I, slow skeletal muscle                       | - 70.21  | - 10.07  | 0.0005 |
| Omy#S34312003 | similar to Titin (Connectin)                           | - 44.29  | - 29.86  | 0.0013 |
| Omy#S15317515 | Type I keratin E7                                      | 5.08     | 2.43     | 0.0167 |
| Ssa#STIR05140 | Troponin I, slow skeletal muscle                       | - 13.16  | - 14.20  | 0.0124 |
| Ssa#STIR08802 | Myosin regulatory light chain 2, smooth muscle isoform | 1.55     | 1.34     | 0.0324 |

**Miscellaneous/unknown function**

|                 |                                     |        |        |        |
|-----------------|-------------------------------------|--------|--------|--------|
| Ssa#S35519407   | Tetratricopeptide repeat protein 23 | 3.64   | 1.02   | 0.0012 |
| Ssa#S35584894   | NCK-associated protein 1-like       | - 1.82 | - 1.70 | 0.0019 |
| Ssa#S35521859_S | FAM36A                              | 1.11   | 5.75   | 0.0047 |
| Ssa#STIR02307   | FAM36A                              | 1.16   | 3.31   | 0.0058 |
| Ssa#TC87798     | Envelope polyprotein                | - 1.83 | - 1.03 | 0.0233 |

|                |   |        |        |        |
|----------------|---|--------|--------|--------|
| Ssa#STIR20319  | TPA-induced transmembrane protein                 | - 1.09 | 1.75   | 0.0233 |
| Ssa#TC110493_S | Beta-3-galactosyltransferase                      | 6.80   | 1.80   | 0.0233 |
| Ssa#S30270166  | Transmembrane protein 37                          | 2.13   | 1.90   | 0.0254 |
| Ssa#STIR08658  | Tetraspanin-3 putative                            | - 3.20 | - 1.47 | 0.0312 |
| Ssa#S30293470  | Deoxyribonuclease gamma precursor                 | 2.19   | 2.85   | 0.0366 |
| Ssa#S35667723  | Dynein, cytoplasmic 1, light intermediate chain 2 | - 1.90 | - 1.48 | 0.0366 |
| Ssa#CX354464   | Retinol dehydrogenase 12                          | 2.37   | 2.35   | 0.0373 |
| Ssa#S35582016  | Type I iodothyronine deiodinase                   | 1.51   | 1.74   | 0.0380 |
| Ssa#S35515630  | C7orf57   | 1.32   | 1.13   | 0.0380 |
| Ssa#STIR15617  | FAM36A  | 1.02   | 4.60   | 0.0403 |
| Ssa#STIR31448  | osteopontin-like                                  | - 4.84 | - 1.58 | 0.0419 |
| Ssa#STIR26263  | Anterior gradient protein 2 homolog precursor     | 3.72   | 1.68   | 0.0419 |
| Ssa#TC65497_S  | Adipocyte plasma membrane-associated protein      | 2.50   | 1.64   | 0.0419 |
| Ssa#TC93681    | Ring finger protein 44                            | - 1.23 | - 1.17 | 0.0455 |
| Ssa#EG819142   | GlutaminyI-peptide cyclotransferase-like          | - 1.11 | - 1.49 | 0.0455 |

---

**Table 4 Lipid metabolism genes differentially expressed in the liver of fish having high or low flesh n-3 LC-PUFA contents.** Results were obtained by two-way ANOVA analysis ( $p < 0.05$ ; fold change cut-off of 1.2) without multiple testing correction ( $n=1951$  total features). Transcripts are arranged by functional categories and, within these, by p-value. Indicated are also the probe names and the expression ratio between families determined separately for each total lipid level.

| Probe name   | Gene   | High/Low LC-PUFA   |                    | p-value |
|--|--|--------------------|--------------------|---------|
|  |  | L Lipid<br>(LH/LL) | H Lipid<br>(HH/HL) |         |
| <b>Cholesterol biosynthesis, metabolism and regulation</b> |  |                    |                    |         |
| Omy#S15288895  | Sterol-C4-methyl oxidase-like  | 1.84               | 1.32               | 0.0033  |
| Ssa#STIR00031_3  | 7-dehydrocholesterol reductase ( <i>7dchr</i> )                            | - 1.55             | - 1.48             | 0.0036  |
| Ssa#S30286041  | 7-dehydrocholesterol reductase ( <i>7dchr</i> )                            | - 1.48             | - 1.42             | 0.0120  |
| Omy#CF752841   | Sterol regulatory element-binding transcription factor 2 ( <i>srebp2</i> ) | - 1.71             | - 1.31             | 0.0170  |
| Ssa#TC102141   | Cytochrome P450, family 27, subfamily A, polypeptide 1                     | - 3.97             | - 1.04             | 0.0192  |
| Ssa#STIR16974  | 7-dehydrocholesterol reductase ( <i>7dchr</i> )                            | - 1.46             | - 1.31             | 0.0195  |
| Ssa#AM402497   | Hydroxymethylglutaryl-CoA synthase 1                                       | - 2.39             | 1.21               | 0.0199  |
| Ssa#STIR00031_4  | 7-dehydrocholesterol reductase ( <i>7dchr</i> )                            | - 1.41             | - 1.46             | 0.0212  |
| Ssa#STIR00098_4  | Isopentenyl-diphosphate delta isomerise ( <i>ipi</i> )                     | - 2.12             | - 1.15             | 0.0228  |
| Ssa#S18867829  | 7-dehydrocholesterol reductase ( <i>7dchr</i> )                            | - 1.33             | - 1.25             | 0.0228  |
| Ssa#DY741343   | Lanosterol 14-alpha demethylase  | - 1.42             | - 1.28             | 0.0346  |
| Omy#S22913656  | Acetoacetyl-CoA synthetase   | - 1.77             | - 2.52             | 0.0358  |
| Ssa#STIR00033_3  | Mevalonate kinase ( <i>mev</i> )   | - 1.54             | - 1.08             | 0.0393  |
| Ssa#CA064135   | Vigilin  | 2.80               | - 1.22             | 0.0423  |
| Ssa#DW582478   | Cytochrome P450, family 8, subfamily B, polypeptide 1                      | - 1.26             | - 1.50             | 0.0449  |
| Ssa#STIR00102_3  | Squalene epoxidase   | - 2.11             | - 1.36             | 0.0468  |
| <b>Glycerophospholipid synthesis</b>                       |  |                    |                    |         |
| Ssa#STIR39152_S  | Lipid phosphate phosphohydrolase 2 ( <i>lpp2</i> )                         | 1.20               | 1.19               | 0.0177  |
| Ssa#KSS4003  | Chka protein   | 1.18               | 1.53               | 0.0264  |
| Ssa#S3538062_S   | Monoacylglycerol O-acyltransferase 1 ( <i>mgat</i> )                       | 1.20               | 1.51               | 0.0303  |
| Ssa#S31963704  | Diacylglycerol O-acyltransferase homolog 2                                 | 1.41               | 1.02               | 0.0358  |
| Ssa#S48418830  | Phosphatidylglycerophosphate synthase 1                                    | - 1.52             | - 1.72             | 0.0369  |
| <b>Fatty acid synthesis</b>                                |  |                    |                    |         |
| Ssa#KSS4155  | Trans-2-enoyl-CoA reductase, mitochondrial precursor                       | - 1.26             | - 1.25             | 0.044   |
| <b>Intracellular fatty acid transport</b>                  |  |                    |                    |         |
| Ssa#S35585414  | Acyl-CoA-binding protein   | 10.47              | 1.65               | 0.0081  |
| Ssa#DY703528   | Fatty acid-binding protein, intestinal                                     | - 1.25             | - 1.46             | 0.0331  |
| Ssa#CB509140   | Fatty acid-binding protein, intestinal                                     | - 1.20             | - 1.35             | 0.0375  |
| Ssa#STIR04578  | Fatty acid-binding protein, heart  | 1.22               | 1.47               | 0.0401  |
| <b>Lipid transport</b>                                     |  |                    |                    |         |
| Ssa#CK898816   | Low density lipoprotein receptor-related protein 1 ( <i>lrp1</i> )         | - 1.14             | - 1.39             | 0.0341  |
| Ssa#S32008850  | Apolipoprotein A-IV precursor ( <i>apoa4a</i> )                            | - 1.43             | - 1.01             | 0.0377  |
| Omy#BX318293   | Low density lipoprotein receptor-related protein 1 ( <i>lrp1</i> )         | - 3.61             | - 1.67             | 0.0404  |

|  |  |        |         |        |
|--|--|--------|---------|--------|
| Ssa#S18866963                              | Apolipoprotein A-IV precursor ( <i>apoA4b</i> )  | - 1.39 | - 1.43  | 0.0428 |
| <b>Lipid hydrolysis</b>                    |  |        |         |        |
| Ssa#S18887340                              | Acyl-coenzyme A thioesterase 5   | 1.64   | 1.18    | 0.0007 |
| Ssa#STIR02708                              | Isoamyl acetate-hydrolyzing esterase 1 homolog<br>Similar to patatin-like phospholipase domain<br>containing 7 | 1.54   | 1.12    | 0.0013 |
| Ssa#DW007099                               | Acyl-CoA thioesterase 11   | - 3.75 | - 2.37  | 0.0070 |
| Ssa#S31963297                              | N-acylsphingosine amidohydrolase 1   | 1.35   | 1.38    | 0.0097 |
| Ssa#STIR07750                              | Isoamyl acetate-hydrolyzing esterase 1 homolog   | - 1.14 | - 1.34  | 0.0122 |
| Ssa#STIR05034                              | Acyl-coenzyme A thioesterase 3   | 1.74   | 1.01    | 0.0208 |
| Omy#CA366823                               | Lipoprotein lipase ( <i>lpl</i> )  | 1.33   | 2.17    | 0.0248 |
| Ssa#STIR22551                              |  | 1.31   | 1.31    | 0.0346 |
| <b>Eicosanoid synthesis and metabolism</b> |  |        |         |        |
| Ssa#TC68569                                | Thromboxane-A synthase ( <i>thas</i> )   | - 1.33 | - 1.67  | 0.0269 |
| Ssa#TC110080                               | Phospholipase A2 ( <i>pla2g4</i> )   | 1.26   | 1.08    | 0.0296 |
| Omy#TC147730                               | Prostaglandin I2 (prostacyclin) synthase ( <i>ptgis</i> )  | - 2.53 | - 4.25  | 0.0349 |
| Ssa#S35581706                              | 15-hydroxyprostaglandin dehydrogenase  | - 1.51 | - 1.09  | 0.0400 |
| Ssa#EG930234                               | Arachidonate 5-lipoxygenase ( <i>alox5</i> )   | 1.91   | 1.55    | 0.0449 |
| <b>Regulation of lipid metabolism</b>      |  |        |         |        |
| Ssa#TC112002                               | Retinoid X receptor beta   | 1.00   | - 19.09 | 0.0000 |
| Ssa#KSS2129                                | Adiponectin receptor protein 1   | - 1.30 | - 1.31  | 0.0098 |
| Ssa#CA056493                               | Angiopietin-like 6<br>Adiponectin, C1Q and collagen domain containing,<br>like                                 | - 1.63 | - 1.07  | 0.0290 |
| Ssa#S35490606                              |  | 1.34   | 1.66    | 0.0441 |
| Ssa#S18888608                              | Adiponectin receptor protein 1   | - 1.38 | - 1.40  | 0.0451 |

**Table 5 Validation of microarray results and expression of genes of interest in relation to the factor 'n-3 LC-PUFA level'.** Values represent the expression ratios between high PUFA / low PUFA, for fish containing either low or high total lipid levels in their flesh, obtained by microarray analysis or RT-qPCR. Expression ratios in bold were significant by REST2008 analysis of RT-qPCR results.

| Gene  | Low Lipid<br>LH/LL |              | High Lipid<br>HH/HL |              |
|---|--------------------|--------------|---------------------|--------------|
|   | Microarray         | RT-qPCR      | Microarray          | RT-qPCR      |
| <u>LC-PUFA biosynthesis</u>                       |                    |              |                     |              |
| <i>Δ5fad</i>                                      |                    | -1.19        |                     | 1.17         |
| <i>Δ6fad</i>                                      |                    | 1.13         |                     | -1.21        |
| <i>elovl2</i>                                     |                    | 1.14         |                     | 1.06         |
| <u>Cholesterol biosynthesis</u>                   |                    |              |                     |              |
| <i>ipi</i>  | -2.13              | <b>-3.92</b> | -1.15               | 1.32         |
| <i>mev</i>  | -1.54              | -1.51        | -1.08               | 1.06         |
| <i>7dchr</i>                                      | -1.33 to -1.54     | <b>-1.47</b> | -1.25 to -1.47      | <b>-1.34</b> |
| <i>srebp2</i>                                     | -1.72              | <b>-1.68</b> | -1.30               | 1.60         |
| <u>Lipid transport and lipoprotein metabolism</u> |                    |              |                     |              |
| <i>lrp1</i>                                       | -1.14 to -3.57     | -1.36        | -1.39 to -1.67      | 1.24         |
| <i>apoA4a</i>                                     | -1.43              | -1.09        | 1.00                | 1.32         |
| <i>apoA4b</i>                                     | -1.39              | -1.48        | -1.43               | -1.10        |
| <i>lpl</i>  | 1.31               | 1.23         | 1.31                | 1.38         |
| <u>Glycerophospholipid synthesis</u>              |                    |              |                     |              |
| <i>lpp2</i>                                       | 1.20               | -1.19        | 1.19                | 1.30         |
| <i>mgat</i>                                       | 1.20               | 1.04         | 1.51                | <b>1.78</b>  |
| <u>Eicosanoid biosynthesis</u>                    |                    |              |                     |              |
| <i>alox5</i>                                      | 1.91               | <b>1.48</b>  | 1.55                | <b>1.62</b>  |
| <i>pla2g4</i>                                     | 1.26               | -1.08        | 1.08                | 1.06         |
| <i>thas</i>                                       | -1.33              | -1.08        | -1.67               | <b>1.34</b>  |
| <i>ptgis</i>                                      | -2.53              | -1.25        | -4.25               | 1.27         |
| <u>Immune response</u>                            |                    |              |                     |              |
| <i>mal</i>  | -22.20             | <b>-3.70</b> | -25.00              | <b>-5.00</b> |
| <i>ccl13</i>                                      | 4.40               | <b>5.98</b>  | 3.00                | 2.14         |
| <i>trim25</i>                                     | 5.20               | <b>2.80</b>  | 6.70                | <b>2.51</b>  |
| <i>lect2</i>                                      | 4.60               | 1.92         | 7.10                | <b>7.57</b>  |

Delta5 and 6 fatty acyl desaturases (*Δ5fad* and *Δ6fad*); fatty acyl elongase (*elovl2*); isopentenyl-diphosphate isomerase (*ipi*); mevalonate kinase (*mev*); 7-dehydrocholesterol reductase (*7dchr*); sterol regulatory element-binding protein 2 (*srebp2*); low density lipoprotein receptor-related protein 1 (*lrp1*); apolipoprotein A-IV (*apoA4a* and *apoA4b*); lipoprotein lipase (*lpl*); lipid phosphate phosphohydrolase 2 (*lpp2*); monoacylglycerol O-acyltransferase 1 (*mgat*); arachidonate 5-lipoxygenase (*alox5*); phospholipase A2 (*pla2g4*); thromboxane-A synthase (*thas*); prostaglandin I2 (prostacyclin) synthase (*ptgis*); myelin and lymphocyte protein (*mal*); c-c motif chemokine 13 precursor (*ccl13*); tripartite motif-containing protein 25 (*trim25*); leukocyte cell-derived chemotaxin 2 precursor (*lect2*).

**Table 6 Validation of microarray results and expression of genes of interest in relation to the factor 'Lipid level'.** Values represent the expression ratios between high lipid / low lipid, for fish containing either low or high n-3 LC-PUFA levels in their flesh, obtained by microarray analysis or RT-qPCR. Expression ratios in bold were significant by REST2008 analysis of RT-qPCR results.

| Gene  | Low n-3 LC-PUFA<br>HL/LL |              | High n-3 LC-PUFA<br>HH/LH |              |
|---|--------------------------|--------------|---------------------------|--------------|
|   | Microarray               | RT-qPCR      | Microarray                | RT-qPCR      |
| <u>LC-PUFA biosynthesis</u>                       |                          |              |                           |              |
| <i>Δ5fad</i>                                      |                          | -1.03        |                           | <b>1.35</b>  |
| <i>Δ6fad</i>                                      |                          | 1.04         |                           | -1.32        |
| <i>elovl2</i>                                     | -1.28 to -1.41           | <b>-1.51</b> | -1.82 to -1.97            | <b>-1.62</b> |
| <u>Cholesterol biosynthesis</u>                   |                          |              |                           |              |
| <i>ipi</i>  |                          | <b>-3.95</b> |                           | 1.31         |
| <i>mev</i>  |                          | -1.40        |                           | 1.14         |
| <i>7dchr</i>                                      |                          | -1.01        |                           | 1.09         |
| <i>srebp2</i>                                     |                          | <b>-2.09</b> |                           | 1.29         |
| <u>Lipid transport and lipoprotein metabolism</u> |                          |              |                           |              |
| <i>lrp1</i>                                       |                          | <b>-1.82</b> |                           | -1.08        |
| <i>apoA4a</i>                                     |                          | <b>-1.37</b> |                           | -0.95        |
| <i>apoA4b</i>                                     |                          | <b>-2.43</b> |                           | <b>-1.80</b> |
| <i>lpl</i>  |                          | -1.18        |                           | -1.05        |
| <u>Immune response</u>                            |                          |              |                           |              |
| <i>cfh</i>  | -1.33 to -1.56           | -1.24        | -1.56 to -1.69            | <b>-1.31</b> |
| <i>trim25</i>                                     | -5.64                    | <b>-2.09</b> | -4.34                     | -2.33        |
| <i>lect2</i>                                      | 3.16                     | 1.23         | 4.86                      | <b>4.84</b>  |

Delta5 and 6 fatty acyl desaturases (*Δ5fad* and *Δ6fad*); fatty acyl elongase (*elovl2*); isopentenyl-diphosphate isomerase (*ipi*); mevalonate kinase (*mev*); 7-dehydrocholesterol reductase (*7dchr*); sterol regulatory element-binding protein 2 (*srebp2*); low density lipoprotein receptor-related protein 1 (*lrp1*); apolipoprotein A-IV (*apoA4a* and *apoA4b*); lipoprotein lipase (*lpl*); complement factor H precursor (*cfh*); tripartite motif-containing protein 25 (*trim25*); leukocyte cell-derived chemotaxin 2 precursor (*lect2*).

**Table 7 Primers used for RT-qPCR analyses**

| Transcript     | Primer sequence (5'-3')                               | Fragment | Ta    | Efficiency | Accession No.             | Source     |
|----------------|---|----------|-------|------------|---------------------------|------------|
| <i>Δ5fad</i>   | GTGAATGGGGATCCATAGCA<br>AAACGAACGGACAACCAGA           | 192 bp   | 56°C  | 0,945      | AF478472 <sup>1</sup>     | [9]        |
| <i>Δ6fad_a</i> | CCCCAGACGTTTGTGTCAG<br>CCTGGATTGTTGCTTTGGAT           | 181 bp   | 56°C  | 0,928      | AY458652 <sup>1</sup>     | [9]        |
| <i>elovl2</i>  | CGGGTACAAAATGTGCTGGT<br>TCTGTTTGCCGATAGCCATT          | 145 bp   | 60°C  | 0,926      | TC91192 <sup>2</sup>      | [24]       |
| <i>ipi</i>     | ACAGCCCTATGGTTATGTGTCATCTC<br>CAAGGTGAGGCGAATGTTTGAAC | 230 bp   | 60°C  | 0,985      | CK875291 <sup>1</sup>     | [11]       |
| <i>mev</i>     | CCCTTAATCAGGGTCCCAAT<br>GGTGCTGGTTGATGTCAATG          | 247 bp   | 60°C  | 0,910      | DW005667 <sup>1</sup>     | [11]       |
| <i>7dchr</i>   | CCTTCTGGAATGAGGCATGGT<br>ACAGGTCCTTCTGGTGGTTG         | 230 bp   | 60°C  | 0,977      | TC99602 <sup>2</sup>      | [11]       |
| <i>sreb2</i>   | GACAGGCACAACACAAGGTG<br>CAGCAGGGGTAAGGGTAGGT          | 215 bp   | 60°C  | 0,887      | DY733476 <sup>1</sup>     | [11]       |
| <i>lrp1</i>    | ACCAACCGCATCTACTGGAC<br>CAGATTACCAGCCACCCAGT          | 204 bp   | 60°C  | 0,996      | CK898816 <sup>1</sup>     | New design |
| <i>apoA4a</i>  | CCCAAACCAACACCACTCCT<br>GGTTTATATTTCTCACCCCTGCAC      | 150 bp   | 60°C  | 0,997      | BT047465 <sup>1</sup>     | New design |
| <i>apoA4b</i>  | CTCTTGCCCTCTTGATGACTG<br>TGACTCATCAGAGCCAATTCA        | 154 bp   | 60°C  | 0,918      | BT047267 <sup>1</sup>     | New design |
| <i>lpl</i>     | AGGGCGTTAATCCATGTCAG<br>GACCTTTCAAAAGGGCATGA          | 223 bp   | 60°C  | 0,917      | TC84899 <sup>2</sup>      | [8]        |
| <i>lpp2</i>    | TCCGGAAGAACTCGCAATAC<br>ACATCACGTCCACCAAGACA          | 174 bp   | 60°C  | 0,926      | NM_001140716 <sup>1</sup> | [9]        |
| <i>mgat</i>    | TTAACCCAAAGATGCTGCAA<br>CACGCAGTTGTCAGTGGTTT          | 157 bp   | 60°C  | 0,977      | EG824440 <sup>1</sup>     | New design |
| <i>alox5</i>   | TATCTCCCTCTCCCTCAGTCC<br>GGTCAGCAGTGCCATCA            | 155 bp   | 56 °C | 0,987      | CX727592 <sup>1</sup>     | [57]       |
| <i>pla2g4</i>  | GTCGCTGGCTGGAGCTGTGG<br>AGCCCTATGGGCCCTGGTCA          | 138 bp   | 60°C  | 0,998      | NM_001141333 <sup>1</sup> | New design |
| <i>thas</i>    | TGTTACACGGACCTGATTC<br>GACCGGATCGTCATTCTGTT           | 150 bp   | 60°C  | 0,986      | NM_001165312 <sup>1</sup> | New design |
| <i>ptgis</i>   | GCGTGTGTTGTGGTCATTACG<br>TTCCCTTAGCAAGGTCTGGA         | 247 bp   | 60°C  | 0,836      | GE778709 <sup>1</sup>     | New design |
| <i>mal</i>     | GGCCTCAGTCAAAGAGGAGA                                  | 156 bp   | 60°C  | 0,946      | NM_001141320 <sup>1</sup> | New design |

|                  |   |        |      |       |                       |            |
|------------------|---|--------|------|-------|-----------------------|------------|
| <i>ccl13</i>     | GGGGAGTGCACACTTTAGGA<br>CGAGGATCCCTCTTCAACAA<br>ATCGTCTGACTAGGCAGCAGT | 178 bp | 60°C | 0,996 | EG831431 <sup>1</sup> | New design |
| <i>trim25</i>    | GCAGGGTCCTATCTCATCCA<br>GGACTGGACCTTTTTATTCTCTCA                      | 215 bp | 60°C | 0,951 | BT048046 <sup>1</sup> | New design |
| <i>lect2</i>     | CTGTGTTGTCAGAGTGCGAGATGGT<br>TACACACAATGTCCAGGCCCTGA                  | 150 bp | 60°C | 0,996 | BT050009 <sup>1</sup> | [58]       |
| <i>cfh</i>       | TGTGATGATGGAGAGATGCAG<br>CAAGCGACAAAGAAACCACA                         | 193 bp | 60°C | 0,966 | TC141997 <sup>2</sup> | New design |
| Reference genes* |   |        |      |       |                       |            |
| <i>elf-1α</i>    | CTGCCCCTCCAGGACGTTTACAA<br>CACCGGGCATAGCCGATTCC                       | 175 bp | 60°C | 1.000 | AF321836 <sup>1</sup> | [11]       |
| <i>β-actin</i>   | ACATCAAGGAGAAGCTGTGC<br>GACAACGGAACCTCTCGTTA                          | 141 bp | 56°C | 0.939 | AF012125 <sup>1</sup> | [11]       |

<sup>1</sup> GenBank (<http://www.ncbi.nlm.nih.gov/>)



<sup>2</sup> Atlantic salmon Gene Index (<http://compbio.dfci.harvard.edu/tgi/>)

\* geNorm average stability (M value) of reference genes = 0.514 [59]

**Additional file 1: Relationship between total lipid level and n-3 LC-PUFA content.**

The graphs show the relationship between total lipid level (g/100g flesh) and n-3 LC-PUFA content as either a relative value ( $\mu\text{g}/\text{mg}$  lipid) – top graph – or an absolute amount (mg/100g flesh) – bottom graph. Indicated are the correlation coefficients ( $r$ )

[and associated p-values](#) between both lipid composition parameters. Squares around the data points indicate the four families which were used for molecular analysis.



**Additional file 2: Gene Ontology terms showing significant enrichment in the list of features affected by the 'total lipid' factor.**



GO analysis was conducted at  $p < 0.05$  after two-way ANOVA analysis of the microarray results ( $p < 0.05$ ; fold change cut-off of 1.2; with Benjamini-Hochberg multiple testing correction).

| GO ACCESSION                     | GO Term   | Corrected p-value | % Count in Selection | % Count in Total |
|----------------------------------|---|-------------------|----------------------|------------------|
| GO:0050778                       | positive regulation of immune response                    | 2,9E-07           | 20                   | 0,25             |
| GO:0050776                       | regulation of immune response                             | 2,9E-07           | 20                   | 0,28             |
| GO:0002684                       | positive regulation of immune system process              | 6,2E-07           | 20                   | 0,32             |
| GO:0048584                       | positive regulation of response to stimulus               | 8,7E-07           | 20                   | 0,28             |
| GO:0002682                       | regulation of immune system process                       | 2,6E-06           | 20                   | 0,38             |
| GO:0048583                       | regulation of response to stimulus                        | 4,9E-05           | 20                   | 0,37             |
| GO:0002699                       | positive regulation of immune effector process            | 1,9E-04           | 16                   | 0,08             |
| GO:0002697                       | regulation of immune effector process                     | 4,9E-04           | 16                   | 0,10             |
| GO:0006954                       | inflammatory response                                     | 9,7E-04           | 24                   | 0,40             |
| GO:0001819                       | positive regulation of cytokine production                | 1,1E-02           | 16                   | 0,07             |
| GO:0016614                       | oxidoreductase activity, acting on CH-OH group of donors  | 1,4E-02           | 30                   | 0,63             |
| GO:0006952 GO:0002217 GO:0042829 | defense response  | 1,4E-02           | 28                   | 0,76             |
| GO:0004616                       | phosphogluconate dehydrogenase (decarboxylating) activity | 1,9E-02           | 16                   | 0,07             |
| GO:0006739                       | NADP metabolic process                                    | 2,0E-02           | 16                   | 0,20             |
| GO:0002708                       | positive regulation of lymphocyte mediated immunity       | 2,6E-02           | 12                   | 0,06             |
| GO:0002706                       | regulation of lymphocyte mediated immunity                | 2,6E-02           | 12                   | 0,06             |
| GO:0002705                       | positive regulation of leukocyte mediated immunity        | 2,6E-02           | 12                   | 0,06             |
| GO:0002703                       | regulation of leukocyte mediated immunity                 | 2,6E-02           | 12                   | 0,06             |
| GO:0001817                       | regulation of cytokine production                         | 2,7E-02           | 16                   | 0,08             |
| GO:0019863                       | IgE binding   | 3,3E-02           | 12                   | 0,04             |
| GO:0006766                       | vitamin metabolic process                                 | 3,6E-02           | 18                   | 0,48             |
| GO:0002673                       | regulation of acute inflammatory response                 | 4,4E-02           | 12                   | 0,05             |
| GO:0002675                       | positive regulation of acute inflammatory response        | 4,4E-02           | 12                   | 0,05             |

|                       |  |         |    |      |
|-----------------------|--|---------|----|------|
| GO:0002712            | regulation of B cell mediated immunity   | 4,4E-02 | 12 | 0,05 |
| GO:0002714            | positive regulation of B cell mediated immunity  | 4,4E-02 | 12 | 0,05 |
| GO:0002819            | regulation of adaptive immune response   | 4,4E-02 | 12 | 0,05 |
| GO:0002821            | positive regulation of adaptive immune response  | 4,4E-02 | 12 | 0,05 |
| GO:0002822            | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains          | 4,4E-02 | 12 | 0,05 |
| GO:0002824            | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 4,4E-02 | 12 | 0,05 |
| GO:0002861            | regulation of inflammatory response to antigenic stimulus  | 4,4E-02 | 12 | 0,05 |
| GO:0002863            | positive regulation of inflammatory response to antigenic stimulus   | 4,4E-02 | 12 | 0,05 |
| GO:0002864            | regulation of acute inflammatory response to antigenic stimulus  | 4,4E-02 | 12 | 0,05 |
| GO:0002866            | positive regulation of acute inflammatory response to antigenic stimulus   | 4,4E-02 | 12 | 0,05 |
| GO:0002883            | regulation of hypersensitivity   | 4,4E-02 | 12 | 0,05 |
| GO:0002885            | positive regulation of hypersensitivity  | 4,4E-02 | 12 | 0,05 |
| GO:0002889            | regulation of immunoglobulin mediated immune response  | 4,4E-02 | 12 | 0,05 |
| GO:0002891            | positive regulation of immunoglobulin mediated immune response   | 4,4E-02 | 12 | 0,05 |
| GO:0006098            | pentose-phosphate shunt  | 4,4E-02 | 16 | 0,20 |
| GO:0006740            | NADPH regeneration   | 4,4E-02 | 16 | 0,20 |
| GO:0006769            | nicotinamide metabolic process   | 4,4E-02 | 16 | 0,23 |
| GO:0016616            | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor  | 4,4E-02 | 30 | 0,61 |
| GO:0019814            | immunoglobulin complex   | 4,4E-02 | 14 | 0,08 |
| GO:0019882 GO:0030333 | antigen processing and presentation  | 4,4E-02 | 14 | 0,24 |

---

**Additional file 3: Distribution of IPN resistance scores in relation to flesh lipid phenotypes.** The plots show estimated breeding values (EBV) for IPN survival (logit transformation of data where 0=dead and 1=alive), assessed by a freshwater experimental challenge, in relation to either total lipid level (g/100g flesh) (upper panel) or absolute n-3 LC-PUFA content (mg/100g flesh) (lower panel) of all families in the selection program. Indicated (squares around the data points) are the four families used for molecular analysis.



**Additional file 4: Genes similarly regulated in pair-wise comparisons of families containing H and L n-3 LC-PUFA flesh contents, at each one of the total lipid levels.** Two t-tests (unpaired unequal variance, Welch, asymptotic) with no multiple testing correction, at  $p < 0.05$  and fold change  $> 1.2$ , were performed, each comparing the two families presenting higher and lower n-3 LC-PUFA contents at either one of the total lipid levels: HH/HL and LH/LL. This returned a list of 1604 or 1305 entities for the comparison in the low or high total lipid grouping, respectively. A Venn diagram was subsequently performed with these two lists and a Venn list containing only the genes that were present in both t-test lists was retrieved. The Venn list contained 149 entities but, of these, only 64 entities presented a similar regulation (up- or down-regulated in both lists). These were then categorized according to their biological function (9% unknowns) and are presented in the table. Indicated are also the probe names, the expression ratio for HH/HL and LH/LL comparisons, and their respective p-values. Percent representation of genes by category of biological function (after removing unknown and genes with miscellaneous function, as well as repeated probes for the same gene) is also shown.

| Probe name                                    | Gene                                    | <u>Hi/Lo LC-PUFA</u> |                  | <u>p- value</u>  |                  |
|---|---|----------------------|------------------|------------------|------------------|
|   |   | H Lipid<br>HH/HL     | L Lipid<br>LH/LL | H Lipid<br>HH/HL | L Lipid<br>LH/LL |
| <b>Metabolism (9%)</b>                        |   |                      |                  |                  |                  |
| <i>Energy metabolism (3%)</i>                 |   |                      |                  |                  |                  |
| Ssa#S31991256                                 | Isocitrate dehydrogenase 3 (nad+)       | - 1.7                | - 1.9            | 0.0233           | 0.0046           |
| <i>Xenobiotic and oxidant metabolism (6%)</i> |   |                      |                  |                  |                  |
| Ssa#STIR00161_3                               | Cytochrome P450 1A                      | 1.8                  | 2.5              | 0.0045           | 0.0047           |
| Con_CANDS_13                                  | Cytochrome P450 1A                      | 1.4                  | 2.0              | 0.0071           | 0.0101           |
| Ssa#S18892279                                 | Cytochrome P450 1A                      | 1.4                  | 1.8              | 0.0112           | 0.0041           |
| Ssa#STIR05682                                 | Peroxiredoxin 5                         | 1.3                  | 1.4              | 0.0122           | 0.0207           |
| Ssa#STIR00161_4                               | Cytochrome P450 1A                      | 1.5                  | 2.1              | 0.0210           | 0.0145           |
| Ssa#STIR00161_2                               | Cytochrome P450 1A                      | 1.4                  | 1.9              | 0.0286           | 0.0019           |
| <b>Translation (6%)</b>                       |   |                      |                  |                  |                  |
| Ssa#KSS2048                                   | Mitochondrial ribosomal protein S33     | - 1.8                | - 1.9            | 0.0028           | 0.0171           |
| Ssa#S30281303                                 | Mitochondrial 28S ribosomal protein S33 | - 1.7                | - 1.7            | 0.0105           | 0.0395           |
| Ssa#S18867312                                 | Ribonuclease UK114                      | 1.4                  | 1.4              | 0.0132           | 0.0030           |
| <b>Regulation of transcription (28%)</b>      |   |                      |                  |                  |                  |
| Ssa#S35481301                                 | TIP120 protein                          | 3.4                  | 3.1              | 0.0019           | 0.0471           |

|  |   |        |        |        |        |
|--|---|--------|--------|--------|--------|
| Ssa#S35664778                                    | Zinc finger protein 41  | 1.5    | 1.5    | 0.0037 | 0.0245 |
| Omy#S18104058                                    | Zinc finger protein 235   | 2.3    | 4.1    | 0.0208 | 0.0006 |
| Ssa#S31964227                                    | Similar to GTF2I repeat domain containing 2   | 2.5    | 3.3    | 0.0224 | 0.0161 |
| Ssa#CN181117                                     | U2-associated protein SR140 (140 kDa Ser/Arg-rich domain protein)                           | 3.1    | 4.4    | 0.0242 | 0.0068 |
| Ssa#S18880068                                    | SET and MYND domain-containing protein 3  | 1.8    | 2.1    | 0.0244 | 0.0313 |
| Ssa#S35500885                                    | Transcription factor 15   | 3.7    | 3.5    | 0.0262 | 0.0355 |
| Omy#TC171818                                     | Zinc finger CCCH domain-containing protein 14   | 1.3    | 1.5    | 0.0279 | 0.0287 |
| Ssa#S31985656                                    | Prolactin regulatory element-binding protein  | 2.4    | 4.4    | 0.0329 | 0.0116 |
| Ssa#TC97482                                      | CREB binding protein transcript variant   | 2.9    | 3.6    | 0.0355 | 0.0342 |
| <b>Signalling and protein modification (22%)</b> |   |        |        |        |        |
| Ssa#S35552908                                    | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide | - 2.1  | - 1.6  | 0.0037 | 0.0395 |
| Ssa#CA055651                                     | Serine/threonine-protein phosphatase 6  | 13.0   | - 6.5  | 0.0091 | 0.0193 |
| Ssa#STIR07369                                    | Serine threonine protein kinase raf1  | 1.3    | 1.8    | 0.0118 | 0.0033 |
| Omy#TC167859                                     | Regulator of calcineurin family member  | - 1.4  | - 1.4  | 0.0139 | 0.0418 |
| Ssa#S30241573                                    | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide | - 1.5  | 1.3    | 0.0187 | 0.0499 |
| Ssa#STIR31840                                    | Sphingomyelin phosphodiesterase acid transcript variant 1                                   | 2.3    | 2.1    | 0.0238 | 0.0003 |
| Ssa#S23659857                                    | Sphingomyelin phosphodiesterase acid transcript variant 1                                   | 2.0    | 1.6    | 0.0278 | 0.0100 |
| Ssa#STIR23254                                    | Serine/threonine-protein phosphatase 2A regulatory subunit B subunit gamma                  | 1.2    | 1.7    | 0.0286 | 0.0053 |
| Ssa#S35559485                                    | P2Y purinoceptor 1  | 1.4    | 1.4    | 0.0414 | 0.0046 |
| Ssa#STIR11129                                    | Ras-related protein Rap-2b precursor putative   | - 4.5  | - 5.8  | 0.0460 | 0.0071 |
| <b>Immune response (36%)</b>                     |   |        |        |        |        |
| Ssa#S35581943                                    | Myelin and lymphocyte protein   | - 25.0 | - 22.2 | 0.0004 | 0.0059 |
| Ssa#S35558945                                    | Tripartite motif-containing protein 25  | 6.5    | 4.8    | 0.0011 | 0.0240 |
| Ssa#S35536179                                    | novel NACHT domain containing protein   | 1.8    | 2.4    | 0.0016 | 0.0018 |
| Ssa#S35516341                                    | Tripartite motif-containing protein 25  | 6.7    | 5.2    | 0.0023 | 0.0044 |
| Ssa#STIR02298                                    | C-C motif chemokine 13 precursor putative   | 3.0    | 4.4    | 0.0029 | 0.0015 |
| Ssa#TC70262                                      | Cathepsin K   | 2.3    | 1.4    | 0.0050 | 0.0153 |
| Ssa#KSS3969                                      | Leukocyte cell-derived chemotaxin 2 precursor   | 7.1    | 4.6    | 0.0071 | 0.0008 |
| Ssa#S30265745                                    | Bleomycin hydrolase   | - 1.6  | - 1.6  | 0.0127 | 0.0056 |
| Ssa#TC93758                                      | BOLA class I histocompatibility antigen, alpha chain BL3-7 precursor                        | - 9.0  | - 18.6 | 0.0133 | 0.0473 |
| Ssa#STIR21287                                    | Solute carrier family 30 (zinc transporter)member 7   | 1.5    | 2.1    | 0.0134 | 0.0006 |
| Ssa#STIR29382                                    | Rhamnose-binding lectin WCL1  | 1.4    | 1.5    | 0.0165 | 0.0375 |
| Ssa#S29966058                                    | MHC class I antigen   | 8.4    | 1.9    | 0.0171 | 0.0457 |
| Ssa#S35566535                                    | CD4   | 1.6    | 1.6    | 0.0266 | 0.0040 |
| Ssa#S19108411                                    | Rhamnose-binding lectin WCL1  | 1.3    | 1.5    | 0.0343 | 0.0111 |
| Ssa#S35509469                                    | GTPase IMAP family member 7   | 1.7    | 4.0    | 0.0417 | 0.0043 |
| <b>Miscellaneous/unknown function</b>            |   |        |        |        |        |
| Ssa#STIR09736                                    | Transmembrane protein 42  | 1.9    | 2.3    | 0.0004 | 0.0005 |
| Ssa#STIR02934                                    | Ripply2 protein   | - 2.0  | - 2.0  | 0.0009 | 0.0242 |
| Ssa#DW552272                                     | Usher syndrome 1C (autosomal recessive, severe)   | - 16.2 | - 8.1  | 0.0037 | 0.0308 |
| Ssa#S18842295                                    | Alveolin  | 4.6    | 1.7    | 0.0081 | 0.0001 |
| Ssa#TC110572                                     | Usher syndrome 1C (autosomal recessive, severe)   | - 9.1  | - 3.6  | 0.0093 | 0.0415 |
| Omy#CX031967                                     | X-ray repair complementing defective repair in Chinese hamster cells 3                      | - 2.1  | - 3.1  | 0.0174 | 0.0280 |
| Ssa#S30242447                                    | Serine protease HTRA1   | - 2.3  | - 3.8  | 0.0281 | 0.0361 |
| Omy#S15322430                                    | Oxidative stress induced growth inhibitor 1   | - 1.4  | - 1.3  | 0.0312 | 0.0489 |
| Ssa#CB517995                                     | Neurologin 3  | 3.8    | 4.3    | 0.0341 | 0.0344 |
| Ssa#DY726487                                     | WD repeat domain 44   | - 3.8  | - 3.5  | 0.0428 | 0.0098 |
| Ssa#S35564744                                    | Claudin 10  | 2.1    | 4.6    | 0.0473 | 0.0191 |
| Omy#S19712209                                    | N-acylglucosamine 2-epimerase   | - 2.7  | - 6.0  | 0.0482 | 0.0382 |
| Ssa#STIR11043                                    | Golgi autoantigen, golgin subfamily b, macrogolgin (with transmembrane signal), 1 (GOLGB1)  | - 1.4  | - 1.8  | 0.0500 | 0.0118 |